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In  acute  myeloid  leukaemia  (AML),  further  prognostic  determinants  are 
required  in  addition  to  cytogenetics  to  predict  patients  at  increased  risk  of 
relapse. Recent studies have indicated an internal tandem duplication (ITD) in 
the FLT3  gene may adversely affect clinical outcome. The studies reported in 
this  thesis  evaluated  the  impact  of a  FLT3/ITD  on  outcome  in  854  patients 
treated in UK MRC AML trials. A FLT3/ITD was present in 27% patients and 
was associated with leucocytosis and a high percentage of bone marrow blast 
cells.  With respect to  clinical  outcome  it predicted  for  increased relapse  risk 
(RR),  adverse  disease-free  survival  (DFS),  event-free  survival  (EFS)  and 
overall survival (OS).  In multivariate analysis, presence of a mutation was the 
most  significant  prognostic  factor  predicting  for  RR  and  DFS.  In  order  to 
evaluate whether FLT3 mutations can be used as markers of minimal residual 
disease,  paired  presentation  and  relapse  samples  were  studied.  Twenty  four 
patients were wild type FLT3 at diagnosis and 4 acquired a FLT3 mutation at 
relapse.  Of 20 patients positive at diagnosis,  5  who were  all originally ITD+, 
had  no  detectable  mutation  at  relapse.  Furthermore,  another  patient  had  a 
completely  different  ITD  at  relapse  which  could  not  be  detected  in  the 
presentation sample. These results suggest that, at least in some patients, FLT3 
mutations  are  secondary  events  in  leukaemogenesis,  are  unstable  and  thus 
should be used cautiously for the detection of minimal residual disease. Given 
the high frequency of activating FLT3 mutations in patients with AML, FLT3 
and  its  downstream  pathway  are  attractive  targets  for  directed  inhibition. 
Several promising tyrosine kinase  inhibitors have recently been identified and 
in vitro data reported here suggest that FLT3  inhibitors may have a role either 
as  monotherapy  or  in  combination with  conventional  cytotoxic  agents  in the 
treatment of AML.
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12Chapter 1
1.1 Acute myeloid leukaemia
Acute myeloid leukaemia (AML) is characterised by an increase in the number 
of myeloid  cells  in  the  bone  marrow  and  an  arrest  in  their  maturation.  The 
abnormal  proliferation  of  leukaemic  cells  gradually  replaces  the  normal 
haemopoietic  tissue,  resulting  in  bone  marrow  insufficiency.  This  can  be 
manifested  either  as  anaemia,  leucopenia,  thrombocytopenia  or  combined 
cytopenia(s).
The incidence of AML increases with age and ranges from 0.7 to 3.9 cases per
100,000  between 0 and 60 years of age, and from 6.7 to 19.2 cases per 100,000 
above 60 years (Ries et al,  1999). Although the aetiology is unknown, AML is 
strongly  linked  to  radiation,  prior  exposure  to  alkylating  agents  and 
epipodophyllotoxins, and exposure to chemicals such as benzene. For example, 
there  was  a  20  fold  increase  of AML  in  Japanese  people  who  survived  the 
atomic bomb, and a  10 fold increase has been reported in workers exposed to 
benzene (Preston et al,  1996; Linet & Cartwright,  1996). Patients with certain 
congenital  disorders  such  as  Down’s  syndrome,  Fanconi’s  anaemia, 
Klinefelter’s syndrome, Turner’s syndrome and Wiskott-Aldrich syndrome are 
also at higher risk of developing leukaemia.
1.2 Classification and diagnosis of AML
The clinical signs and symptoms of AML are very diverse and mainly related to 
insufficiency of normal haemopoiesis. Patients usually present with symptoms 
of anaemia (fatigue, breathlessness), thrombocytopenia (bleeding and bruising) 
or neutropenia (infections, septicaemia). A combination of the above symptoms 
is  not  unusual,  and  more  rarely,  other  signs  and  symptoms  related  to 
leucocytosis,  coagulopathy,  skin  (leukaemia  cutis)  or  organ  involvement  can 
predominate at presentation.
13Laboratory findings usually reveal pancytopenia, although any combination of 
anaemia,  thrombocytopenia,  and  leucopenia  or  leucocytosis  may  exist.  The 
diagnosis  relies  on  the  morphological  identification  of  myeloblasts  in 
preparations of peripheral blood and bone marrow stained with Wright-Giemsa 
stain.  These  cells  are  usually  large,  have  distinct  nucleoli  and  an  increased 
nucleus  to  cytoplasm  ratio.  The  cytoplasm  may  contain  fine  azurophilic 
granules  and  a  variable  number  of Auer  rods.  Since  1976  AML  has  been 
classified  according  to  the  criteria  of  the  French-American-British  (FAB) 
group,  which  is  based  entirely  on  morphological  and  cytochemical  criteria. 
Morphologic  criteria  are  based  on  two  factors:  the  direction  of  cell  line 
differentiation and the degree of maturation of the proliferating cells. Eight sub­
classifications are recognised from MO to M7: MO with minimal differentiation, 
Ml  without  maturation,  M2  with  maturation,  M3  acute  promyelocytic 
leukaemia,  M4  acute  myelomonocytic  leukaemia,  M5  acute  monocytic 
leukaemia, M6 erythroleukaemia and M7 acute megakaryocytic leukaemia. For 
many  years  FAB  classification  has  facilitated  the  correlation  of clinical  and 
laboratory findings and responses to treatment between clinical trials.
Cytochemistry  allows  the  demonstration  of  specific  enzymes  or  other 
substances  in  individual  cells  and  identifies  cells  across  the  myeloid, 
monocytic,  erythroid,  megakaryocytic  and lymphoid lineages,  complementing 
the  Wright-Giemsa  stain.  Certain  cytochemical  reactions  are  essential  in 
distinguishing  AML  from  acute  lymphoblastic  leukaemia  (ALL).  The 
peroxidase,  Sudan  Black  B  and  chloracetate  esterase  reactions  reveal 
granulocytic differentiation in the Ml, M2, M3 and M4 types of AML, whilst 
the  non-specific  esterases  and  the  acid  phosphatase  and  lysozyme  reactions 
demonstrate  monocytic  differentiation  in  M4  and  M5.  In  erythroleukaemia 
(M6),  the  Periodic  Acid  Schiff (PAS)  reaction  may  be  strongly  positive.  In 
megakaryoblastic  leukaemia  (M7),  the  cytochemical  profile  shows  positive 
reactions with PAS, acid phosphatase and a-naphthyl acetate esterase (ANAE).
14Immunophenotypic analysis by flow cytometry has become a powerful tool for 
accurate  identification  of  myeloid  and  lymphoid  lineage  leukaemias.  An 
important use of flow cytometry is in the identification of AML in minimally 
differentiated and megakaryoblastic leukaemias, where blasts can be small and 
resemble lymphoblasts. The most commonly used monoclonal antibodies in use 
for  the  differentiation  of myeloid  lineage  leukaemias  are  against  HLA  DR, 
CD33 (myeloid cells), CD13, CD14, CD15 (myelomonocytic antigens), CD41, 
CD61  (megakaryocytic antigens), glycophorin and transferrin receptor antigens 
(i.e.  CD71  in erythroleukaemia) and CD2, CD3,  CD4, CD8,  CD19,  CD20 (T 
and B cell antigens). However, leukaemic blasts may aberrantly express some 
antigens of another lineage or lack expression of an expected antigen.
Cytogenetic analysis is an essential component of the diagnosis of AML, with 
approximately  55%  to  80%  of newly  diagnosed  patients  presenting  with  an 
abnormal karyotype. Primary chromosome aberrations are frequently found as 
the  sole  karyotypic  abnormality  and  are  often  specifically  associated  with  a 
particular  AML  subtype.  Secondary  aberrations  are  thought  to  play  an 
important role in the progression of the disease and lead to genomic imbalances 
such  as  gains  or  losses  of  whole  chromosomes,  deletions  or  unbalanced 
translocations.  Secondary  aberrations  may  already  be  present  at  diagnosis  or 
may  appear  for  the  first  time  at  relapse.  Two  major  types  of  primary 
chromosome  abnormalities  can  be  identified  in  AML:  Balanced  structural 
abnormalities  usually  leading  to  a  leukaemia-specific  fusion  transcript,  and 
unbalanced  aberrations  leading  to  gain  and/or  loss  of genetic  material.  The 
most  common  balanced  chromosome  abnormalities  are  t(8;21),  t(l5; 17), 
inv(16)/t(16;16),  and  llq23  abnormalities.  The  most  common  unbalanced 
abnormalities are deletion 5q, monosomy 7, deletion 7q, deletion 9q, trisomy 8, 
11, 13,21,4.
aL
The  4  international  workshop  on  chromosomes  in  leukaemia  was  the  first 
large prospective multi-centre study to establish the role of cytogenetics as an 
independent  prognostic  factor  in  AML  (Bloomfield  et  al,  1984).  Since  then, 
many  studies  have  confirmed  that  pre-treatment  karyotype  constitutes  an 
independent prognostic determinant for attainment of complete remission (CR),
15risk  of  relapse  and  survival.  Three  large  collaborative  studies  have  each 
proposed  a  system  that  assigns  AML  patients  to  one  of  3  risk  groups, 
favourable, intermediate or adverse. These 3  cytogenetic systems assign many 
karyotypic  abnormalities  to  same  risk  group,  however,  there  are  some 
differences. For example, in the MRC classification, any abnormality that is not 
classified as favourable or adverse is classified in the intermediate risk group. 
In contrast, both the Southwest Oncology group/Eastem Cooperative Oncology 
group (SWOG/ECOG) and cancer and Leukaemia group B  (CALGB) classify 
particular  abnormalities  into  risk  groups,  and  leave  as  “not  classified” 
aberrations  too  infrequent  to  be  analysed.  Despite  these  differences,  the 
inv(16)/t(16;16), t(8;21)  and t(l5; 17) have been categorised in the favourable 
group by all three cytogenetic risk systems. They all also agree that prognosis 
of patients  with  inv(3)  or  t(3;3),  -7  and  a  complex  karyotype  is  poor.  The 
definition of complex karyotype differs, though, with the MRC characterising 
this  category  as  the  presence  of  more  than  4  unrelated  cytogenetic 
abnormalities, where as the others use a cut off point of three abnormalities. In 
the  MRC  study,  the  outcome  of patients  with del(7q)  that  was  not part  of a 
complex karyotype and was not accompanied by -5/del(5q) or abn(3q) did not 
differ  significantly  from  outcome  of  patients  with  normal  karyotype,  and 
therefore  these  patients  are  classified  as  having  standard  risk  disease 
(Grimwade et al,  1998). Patients with a normal karyotype are the single largest 
cytogenetic  subset  of  adult  AML.  They  are  classified  in  the  intermediate 
prognostic  category,  as  the  outcome  is  inferior to  those  with  favourable  risk 
disease, but superior to poor risk disease.
1.2.1  WHO classification of  AML
In  1999  the  World  Health  Organisation  (WHO)  proposed  a  classification 
system for haemopoietic and lymphoid neoplasms (Vardiman et al, 2002). In an 
attempt  to  define  biologic  entities  that have  clinical  relevance,  morphologic, 
immunophenotypic,  genetic  and  clinical  features  were  incorporated  in  the 
classification of AML. Four major categories are now recognised:  1) AML with 
recurrent genetic abnormalities, 2) AML with multilineage dysplasia, 3) AML
16and  myelodysplasia  (MDS)  therapy  related  and  4)  AML  not  otherwise 
categorised.
1.3  Treatment of AML
1.3.1 Induction chemotherapy
Although,  AML  was  a  fatal  disease  30  years  ago,  improvements  have  been 
made  since then as a consequence of a more intensive approach to treatment. 
With  current  protocols  in  adult  patients  below the  age  of 60  years,  80%  of 
patients will enter complete remission (CR) and a substantial number will be 
cured (Grimwade et al,  1998).  The backbone of induction treatment relies on 
the combination of cytarabine with one of the anthracyclines (i.e. daunorubicin, 
idarubicin, mitoxantrone).  The value of a third drug is controversial, however 
well established in some studies. For example, the Australian Leukaemia study 
group showed a benefit in the arm of patients treated with etoposide as a third 
drug (Bishop et al,  1990). The use of high dose of cytarabine during induction 
chemotherapy has failed to increase the rate of remission (Bishop et al,  1996; 
Weick  et  al,  1996),  however,  it  can  favourably  affect  relapse  and  overall 
survival (Bishop et al, 1996).
1.3.2 Post induction chemotherapy
Once patients achieve CR, further treatment is essential to prevent subsequent 
relapse,  and  increase  survival  rate.  In younger patients  this  treatment can be 
administered in the form of either chemotherapy, autologous transplantation, or 
allogeneic transplantation using sibling or alternative donors.
1.3.3 Autologous transplantation
Several studies in Europe and the United States have been conducted aiming to 
evaluate  the  potential  benefit of autologous  transplantation  over conventional 
chemotherapy (EORTC-GIEMMA, GOELAM and US  Intergroup) (Zittoun et 
al,  1997;  Harousseau  et  al,  1997;  Cassileth  et  al,  1998),  or  in  addition  to
17chemotherapy (MRC) (Burnett et al,  1998). Generally, all studies have shown a 
reduction in relapse risk, however, this could not be translated into a survival 
benefit  (Zittoun  et  al,  1997;  Harousseau  et  al,  1997;  Cassileth  et  al,  1998; 
Burnett et al,  1998). This can be explained by the fact that some patients in the 
chemotherapy  group  were  able  to  be  salvaged  with  a  transplant  in  second 
complete remission (CR2). It is worth mentioning that both the GOELAM and 
the US  Intergroup studies demonstrated a better survival in the chemotherapy 
arm, and it is of interest that in both studies high dose cytarabine was included 
in the treatment protocols (Harousseau et al,  1997; Cassileth et al,  1998). The 
MRC  AML  10  trial  addressed  a  different  question,  namely  the  role  of 
autologous transplantation in addition to what was considered to be completed 
induction and  consolidation chemotherapy  (Burnett  et al,  1998).  Like  all the 
other trials, the relapse risk was reduced, however, this was counterbalanced by 
a high risk of death during the procedure, so that the overall survival was not 
improved.  Nevertheless,  a survival  advantage  did become  apparent when the 
follow up exceeded the 2nd year, as patients die from transplant related toxicity 
mainly the first 2 years following the transplant, which compromises survival 
benefit. Despite the evidence of reduced relapse risk in recipients of autologous 
transplantation,  relapse  remains  a major cause  of treatment  failure.  Stem  cell 
contamination by the tumour cells as well as residual disease may account for 
this  increased risk  of relapse.  As  a result,  much  energy  has  been  devoted to 
finding  methods  to  purge  the  bone  marrow/peripheral  blood  stem  cells  of 
contaminated cells, and techniques involving in vitro purging have been applied 
(Gorin et al, 1990). Despite some encouraging results, this method has not been 
widely accepted, especially when identical regimens using un-purged marrow 
produced similar results.
1.3.4  A llogeneic transplantation
Autologous transplantation is a relatively safe procedure, however, its value is 
limited  by  the  lack  of  a  graft-versus-leukaemia  (GVL)  effect.  In  contrast, 
during  the  last  2-3  decades,  data  from  single  institutions  or  registries  have 
demonstrated that allogeneic transplantation introduces a powerful GVL effect. 
Further evidence that a GVL effect exists comes from the higher relapse risk in
18patients who receive  a T-cell depleted transplant and in transplants  involving 
identical twins (Gale et al,  1994). However, the strongest evidence, which has 
been documented by almost every study, is the association of acute or chronic 
graft-versus-host disease (GVHD) with a decreased risk of relapse (Ringden et 
al,  2000).  Undoubtedly,  allogeneic  transplantation  is  the  most  active  anti- 
leukaemic  treatment offering  substantial reduction in relapse,  nevertheless  its 
value still remains controversial. Firstly, increased toxicity associated with the 
procedure  compromises  potential  benefits  associated  with  allogeneic 
transplantation.  Secondly,  patients  who  undergo  transplantation  are  selected 
and  may  represent  patients  with  more  favourable  disease  compared  to  those 
who never receive the transplant as a result of early relapse.
In  an  effort  to  overcome  several  sources  of bias,  investigators  have  tried  to 
evaluate potential efficacy of the transplant with an intention-to-treat analysis. 
Four major prospective trials have been conducted in adult patients with AML 
and all of them have demonstrated a reduced relapse risk for the transplant arm 
compared  to  chemotherapy  (Keating  et  al,  1998;  Harousseau  et  al,  1997; 
Cassileth et al,  1998; Burnett et al,  1998). However, this reduction in relapse 
risk did not translate into a real survival benefit in all studies. In fact, in one of 
the studies (US  Intergroup study) patients in the chemotherapy arm  showed a 
modest  superior  outcome  compared  to  the  transplant  arm  (Cassileth  et  al, 
1998).  Nevertheless,  small  number of patients  and  poor compliance  with the 
transplant allocation may account for these differences. Current practice in the 
UK  is  that  in  good  risk  disease,  transplantation  in  first  remission  is  not 
indicated (Burnett et al,  1998). In poor risk disease, in the absence of effective 
chemotherapy,  allogeneic  transplantation  is  fully justifiable  and  effort  should 
be made for the transplant to be given without delay, once remission has been 
achieved. Given the fact that relapse risk remains high even after the transplant, 
novel approaches will be needed in this group to enhance a potential  survival 
benefit.  Finally, in patients with standard risk disease, there is no convincing 
data to support the routine use of an allogeneic transplant in CR1. As it appears 
that chemotherapy continues to produce improved outcome with time, the role 
of  allograft  in  standard  risk  disease  will  become  more  controversial. 
Nevertheless,  the  limits  of  conventional  chemotherapy  might  have  been
19reached, and therefore novel approaches would probably be needed to increase 
survival rate with a minimum cost in terms of toxicity.  The newly introduced 
reduced  intensity  conditioning  regimens  have  already  been  shown  to  be 
associated with low toxicity, and further studies are warranted to establish their 
efficacy in AML (Martino et al, 2002).
1.3.5 Treatment of relapse
Once relapse has occurred, survival depends on the length of first remission and 
the age of the patient. There is no standard treatment for relapsed disease and 
various protocols are being used. The aim of re-induction is to bring the patient 
back  to  remission  before  receiving  a  bone  marrow  transplant.  In  fact,  if a 
transplant can be  given in 2nd remission, approximately 25%-30% of patients 
can  be  salvaged.  Nevertheless,  even  with  a  transplant,  subsequent  relapse 
remains  a  major  cause  of treatment  failure  and  this  group  of patients  are 
candidates for more experimental treatments.
1.3.6 Future direction in the treatment of  AML
There is no doubt that a new era has emerged for cancer targeted therapy and 
immunotherapy. The metabolic and enzymatic pathways affected by the genetic 
aberrations are potential targets for treatment. Acute promyelocytic leukaemia 
(APL) treated by all trans retinoic acid (ATRA) is the first model of a human 
malignant disease reverted by a differentiating agent. A pharmacologic dose of 
ATRA  overcomes  the  blockage  of  exchange  between  corepressors  and 
coactivators  caused by the fusion protein PML-RARA.  Several  investigations 
have reported clinical benefits during clinical trials of ATRA in the treatment 
of APL, all showing evidence for high efficacy and low toxicity (Fenaux et al, 
1993; Frankel et al,  1994). In the initial report from Huang et al (1998), 23 of 
24  patients  with  APL  achieved  either  partial  remission  (PR)  or  complete 
remission without developing bone marrow hypoplasia.
20Mutations and dysregulation of Ras has been associated with the development 
of myeloid  leukaemias  (Reuter  et  al,  2000).  Famesyl  transferase  inhibitors, 
which target the post-translational modification of ras to prevent the subcellular 
localisation necessary for signal transduction, are another example of targeted 
therapy in the treatment of AML (Lancet et al, 2003).
Cell surface antigens represent another target for novel therapies.  The first of 
these  new  targeted  agents  to  be  approved  by  the  US  food  and  drug 
administration is gemtuzumab ozogamicin. This agent is an immunoconjugate 
of  an  anti-CD33  antibody  chemically  linked  to  potent  cytotoxic  agent, 
calicheamicin  (van  Der  Velden  et  al,  2001).  Clinical  studies  are  also  being 
conducted in Europe and Japan using WT1  (Wilms tumour) peptides  specific 
for the HLA-A2 and A24 alleles as vaccines, although results have not yet been 
reported.
1.4  Haemopoietic  growth  factor  receptor  abnormalities  in  acute 
leukaemias (excluding FLT3)
Clear  evidence  from  animal  models  has  indicated  that  mutations  in  growth 
factor receptors can cause constitutive activation of the receptor which leads to 
oncogenic transformation. The capacity of mutant haemopoietic growth factor 
receptors to  induce  factor-independent cell proliferation and  leukaemogenesis 
was initially appreciated in studies of acute leukaemia viruses of mice, several 
of which contain mutated receptor genes as viral oncogenes. For example, the 
acute  transforming  Hardy-Zuckerman  4  feline  sarcoma  virus  (HZ4-FeSV) 
contains the designated oncogene v-kit, which displays partial homology with 
tyrosine-specific  protein  kinase  oncogenes  (Besmer  et  al,  1986).  As 
haemopoietic  growth  factor  receptors  carry  signals  controlling  blood  cell 
development,  there  is  considerable  interest  in  the  possibility  that  receptor 
abnormalities might contribute to leukaemia. To date, activating mutations have 
been reported  in the  receptors  for macrophage  colony  stimulating  factor (M- 
CSF),  stem  cell  factor  (SCF)  and  granulocyte  colony  stimulating  factor  (G- 
CSF) in human leukaemias, however, their frequency is extremely low, raising
21the  possibility  of  additional  operating  mutations  in  the  same  or  different 
pathways in order to produce a leukaemic phenotype.
1.4.1  M-CSF receptor
The c-fms gene encodes the cell surface receptor for M-CSF, where interaction 
of ligand with the  receptor stimulates proliferation and maturation of cells  in 
the  monocyte/ macrophage  lineage.  The  transforming  capacity  of c-fms  was 
first discovered through analysis of the Susan McDonough feline sarcoma virus 
(SM-FeSV)  (McDonough  et  al,  1971).  The  SM-FeSV  genome  contains  a 
mutated,  constitutively  active  form  of  the  receptor  called  v-fms.  Cells 
expressing this  mutant receptor display  constitutive tyrosine  phosphorylation. 
Its tumouriogenic capacity has also been demonstrated in animal models, where 
transfected bone marrow cells infused into lethally irradiated mice can produce 
erythroleukaemia  or  B-cell  lymphoma  (Heard  et  al,  1987).  In  human 
leukaemias,  c-FMS  expression  has  been  reported  in  30%  of AML  cases  of 
monocytic  lineage  (Ashmun  et  al,  1989;  Rambaldi  et  al,  1988).  Activating 
point mutations at codons Leu301  and Tyr969 of c-FMS have been reported in 
patients with AML and myelodysplastic syndromes (MDS) (Ridge et al,  1990; 
Tobal et al,  1990), although confirmation by enzyme digestion or sequencing 
was not done. Allelic loss of one (hemizygous) or both alleles (homozygous) of 
the  c-FMS  gene  has  also  been  reported  in  patients  with  myelodysplasia, 
chromosome  5  deletion  and  AML  (Boultwood  et  al,  1991;  McGlynn  et  al, 
1997).  McGlynn  et  al  (1997),  using  a  semi-quantitative  Southern  blotting 
technique, found that loss of one allele occurred in 5/18 cases of AML M4 and 
8/27  cases  of AML  Ml,  M2  and  M3.  In  addition,  loss  of both  FMS  alleles 
occurred in 3/18 cases of AML M4.
221.4.2  G-CSF receptor
Mutations  in the  G-CSF  receptor  gene  have  been  detected  in  approximately 
20% of patients with severe congenital neutropenia (SCN). These mutations are 
mainly  located  in  a  critical  cytoplasmic  region  (spanning  nucleotides  2384- 
2429), and lead to truncation of the distal cytoplasmic region of the receptor, 
with  subsequent  disruption  in  downstream  signalling.  When  expressed  in 
myeloid  murine  L-GM  cells,  a  truncated  G-CSF  receptor  transduced  a 
proliferative  signal  in  response  to  G-CSF,  but  was  unable  to  signal 
differentiation  (Dong  et  al,  1993).  These  data  implicate  G-CSF  receptor 
truncation  as  a possible  leukaemogenic  mechanism,  because  cells  carrying  a 
mutant receptor may have a growth advantage due to prolonged activation of 
the  receptor  in  the  presence  of the  ligand.  This  is  also  consistent  with  the 
natural  history of the disease,  as patients  with  SCN carrying these  mutations 
have  a  strong  predisposition to  AML  (Dong  et al,  1997).  However,  in mice 
these mutations have not caused leukaemia (Hermans et al,  1998; Me Lemore 
etal, 1998).
In AML, mutations in the G-CSF receptor are rare events. Bernard et al (1996) 
using  SSCP  analysis  in  40  patients  with  AML  identified  a  substitution  at 
nucleotide 2088 which changes a threonine to asparagine at amino acid 617 in 
the transmembrane domain. However, it was not clear whether this base change 
was a leukaemia-specific mutation or an infrequent polymorphism because no 
remission  blood  or  marrow,  constitutive  DNA  or  family  members  were 
available  for  study.  Subsequently,  the  same  group,  in  order  to  determine 
whether it was  a leukaemia-specific mutation,  screened this nucleotide  of the 
G-CSF  receptor  in  genomic  DNA  from  a  further  515  patients  with  AML  at 
presentation and identified the same mutation in  1  patient (Forbes et al, 2002). 
This  mutation  was  not  present  in  remission  bone  marrow  from  this  patient, 
indicating that it was leukaemia-specific.  In vitro experiments showed that the 
mutant  receptor  conferred  growth  factor  independence  on  factor  dependent 
Ba/F3  cells,  and  retroviral  transduction  of the  mutant  receptor  into  primary 
CD34+  cells  induced  myeloid  differentiation  in  the  absence  of  G-CSF. 
Nevertheless,  it should be pointed that the  screening method was  specifically
23for this mutation and would not pick up other potentially activating mutations 
in the same region.
1.4.3 C-kit receptor
C-kit is a member of the type III receptor tyrosine kinase family and plays a 
crucial  role  in  normal  haemopoiesis.  Somatic  mutations  causing  constitutive 
activation  of the  receptor  have  been  associated  with  a  number  of different 
neoplastic conditions such as systemic mastocytosis, sinonasal natural killer T- 
cell  lymphomas,  human  gastrointestinal  stromal  tumours  and  myelofibrosis 
(Hirota et al,  1998; Kimura et al, 1997; Nagata et al 1995).
In AML, c-kit is expressed by myeloblasts in approximately 60%-80% of cases, 
as assessed by surface immunostaining or expression of c-kit messenger RNA 
(Ikeda et al,  1991). In AML, activating mutations in the second tyrosine kinase 
domain  (Asp  816)  have  been  reported  in  patients  with  t(8;21)  and  inv(16) 
(Beghini et al, 2000). Gari et al (1999) reported in-frame deletion plus insertion 
mutations in exon 8, corresponding to the fifth immunoglobulin-like domain in 
the extracellular region of the receptor, in 7/21  patients with inv(16) and  1/23 
patients with t(8;21), all of which the codon for Asp419 was involved in all of 
these.  One  patient with  inv(16)  showed  a Val530Ile  substitution  in exon  10. 
More recently, Kohl et al (2005) showed that exon 8 c-kit mutations induced 
receptor hyperactivation in response to  stem cell  factor (SCF),  stimulation in 
terms of proliferation, and resistance to apoptotic cell death (Kohl et al, 2005).
1.4.4 PDGFRp
Rearrangement of the platelet derived growth factor receptor p (PDGFRp) with 
a number of different partner genes is a frequent finding in myeloproliferative 
syndromes  and  chronic  myelomonocytic  leukaemia  (CMML)  (Cross  NC  & 
Reiter,  2002).  PDGFRp  gene rearrangement with  formation of a fusion gene 
was  first  recognised  in  association  with  t(5; 12)(q31  ;p 12),  the  fusion  gene 
formed  being  ETV6-  PDGFRp  (Golub  et al,  1994).  Subsequently,  PDGFRp
24was  found  to  contribute  to  other  fusion  genes  in  patients  with 
myeloproliferative  disorders.  However,  in  AML  such  rearrangements  are 
extremely rare with only two reported cases in the literature, one in transformed 
atypical  CML  with t(5;12)  (ETV6- PDGFRP)  (Wessels  et al,  1993) and the 
other in relapsed AML with t(5;14) (CEV14- PDGFRP) (Abe et al,  1997).
1.4.5 EPO-R
Mutations  with  truncated  EPO-R  have  been  reported  in  benign  human 
erythrocytosis and primary familiar polycythaemia but no pathogenic mutations 
in  human  erythroleukaemias  have  been  identified  so  far  (Le  Couedic  et  al, 
1996).
1.5 Aims of this thesis
Although examples  exist in which receptor mutations  appear to  contribute to 
pre-malignant or overt disease in AML patients, these mutations occur rarely. 
Recently an internal tandem duplication of the juxtamembrane domain coding 
sequence of the FLT3 gene has been described in AML and has been associated 
with adverse outcome. This thesis presents results of studies to investigate the 
incidence,  biological  and  clinical  characteristics  associated  with  FLT3 
mutations in a large cohort of AML patients;  whether these mutations can be 
used  as  markers  of  minimal  residual  disease;  and  the  response  to  FLT3 
inhibitors  in  samples  from  patients  with  newly  diagnosed  AML  with  and 
without  FLT3  mutations,  either  as  monotherapy  or  in  combination  with 
conventional cytarabine.
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2.1  General materials and reagents
All chemicals were provided from Sigma Chemical Co or BDH/Merck unless 
otherwise stated.
Buffers/solutions
lOx TBE Buffer (pH 8.3).  For 1L
Tris  108.9g
Orthoboric acid  55.7g
EDTA  7.4g
2)  DTAB (dodecyltrimethylammonium bromide) (8%). For 50ml
DTAB
NaCl
EDTA
Tris
4.0g
4.4g
0.93g
0.61g
(pH 8.6)
3)  L-Broth medium plates. For 1L
LB medium 
Agar
Ampicillin
16 capsules (Bio 101 Inc.) 
15g (Calbiochem) 
lml lOmg/ml (Gibco)
4) SOC medium. For 100ml
Tryptone  2g
Yeast extract  0.5g
1M NaCl  lml  (pH 7.0)
1MKC1  lml
2M Mg2+  lml
265) Freezing solution FCS 50% (Gibco)
RPMI1640 35% (Gibco) 
15% DMSO
2.2 Extraction of DNA from PB or BM
Method: Approximately  10-50xl06 leukocytes were obtained from buffy coats, 
either  from  BM  or  PB  and  re-suspended  in  2.4ml  PBS  (Gibco).  DTAB 
(dodecyl-trimethyl  ammonium  bromide)  reagent  (4.8ml)  was  added,  mixed 
thoroughly  and  incubated  at  68°C  for  5  minutes.  An  equal  volume  of 
chloroform  (7.2ml)  was  then added to the  lysed  cells,  mixed thoroughly  and 
centrifuged at 3500rpm for 20 minutes. The aqueous layer was decanted into a 
new  15ml centrifuge tube and the DNA precipitated with an equal volume of 
ethanol (100%). The sample was then centrifuged at 3000rpm for 5 minutes to 
pellet the DNA which was transferred to a 1.5ml tube. The DNA was washed in 
lml 75% ethanol, re-suspended in an appropriate volume of water, allowed to 
dissolve thoroughly and stored at 4°C.
2.3 Reverse transcription (RT)
Method:  In a 20pl reaction volume, the  final concentrations were  lx reaction 
buffer, 5.25 mM MgCl2,  1  mM each dNTP, 20 units RNAse inhibitor, 3-5 units 
AMV  (avian  myeloblastosis  virus)  reverse  transcriptase,  250ng  oligo  dT 
(Promega, UK) and 1  pg RNA. Reaction mixtures were incubated at 42°C for 1  
hour  followed by  95°C  for  5  minutes  to  denature  the  enzyme.  The  resulting 
cDNA was stable for several weeks when stored at 4°C.
2.4 Polymerase chain reaction (PCR)
Method: Approximately 1  OOng DNA  was added to a reaction mix containing 1  
x  buffer  [16mM  (NH4)2S04,  67mM  Tris  HC1  pH  8.8,  0.01%  Tween  20], 
l.OmM  MgCl2,  200pM  dNTPs  (Bioline,  London  UK)  and  10  pmols  each 
primer (Oswel/Eurogentec Ltd, Hampshire, UK) in a total volume of 19pl. The
27mix was heated to 95°C for 5 minutes and held at 85°C whilst  1   pi containing 
0.5 units BIOTAQ™ DNA polymerase (Bioline Ltd. London, UK) was added, 
then  30  cycles  each of 95°C  for 30  seconds,  60°C  for  30  seconds  (60°C  for 
FLT3/ITD  and  63°C  for  FLT3/D835  mutations)  and  72°C  for  30  seconds 
performed,  followed  by  5  minutes  at  72°C.  Amplified  products  were 
electrophoresed through 2%  agarose  gels and visualized under UV  light with 
ethidium bromide staining.
2.5 Semi-quantitative PCR
Method: PCR was carried out as described above with the addition of 1  pmol of 
primer  end-labelled  with  y-[32P]-ATP  (3000Ci/mmol,  Amersham  Pharmacia 
Biotech UK Ltd., Little Chalfont, UK). Ten pmols primer was incubated with 
10  units  of  T4  polynucleotide  kinase  (Promega,UK)  in  the  manufacturer’s 
buffer  and  3pl  y-[32P]-ATP  for  30  minutes  at  37°C.  PCR  was  performed  as 
described above, however, the number of amplification cycles was reduced to 
25.  An aliquot  of 2pl  of the PCR product was  added  in 2 pi  of stop  solution 
(0.5M EDTA/glycerol/bromophenol blue),  heated to  95°C  for 5  minutes, was 
immediately placed on ice and subsequently loaded on to the polyacrylamide 
gels.  Products  were  then  electrophoresed  through  denaturing  polyacrylamide 
gels (7M urea,  6% polyacrylamide crosslinker ratio 37.5:1,  0.5  x Tris-Borate- 
EDTA),  the  gels  were  dried  and  exposed  to  Hyperfilm-MP  (Amersham). 
Autoradiographic signals were quantified using densitometry (Hoefer Scientific 
Instruments, San Francisco, CA).
2.6 Sequencing of PCR products
Method:  PCR  products  were  cleaned  using  a  PCR  purification  kit  (Wizard 
PCR preps DNA purification system, Promega, UK) and run on an agarose gel 
for  approximate  quantification.  Sequencing  PCR  was  performed  by  adding 
approximately  lOng cleaned PCR product to a single reaction mix containing 
the  dye  terminators,  DNA  polymerase,  MgCL  and  buffer  (BigDye™ 
Terminator  cycle  sequencing  kit,  Perkin  Elmer,  Boston  MA,  USA).  The 
products  were  subsequently precipitated with 2.0pl  Na  acetate  (3M,  pH  4.6)
28and  50pl  ethanol  (95%)  and washed in 75%  ethanol.  The  samples were then 
dried,  re-suspended  in  15 pi  Template  Suppression  Reagent™  (TSM), 
denatured at 95°C  for 5  minutes and placed on ice before loading on the 310 
Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).
2.7 Cloning of PCR products
Method: PCR products were cloned using the TA cloning system which utilises 
the single deoxyadenosine overhang at the 3' end of PCR products. Two pi of 
PCR product was incubated with  lpl of the T-vector,  lpl T4 DNA ligase and 
5 pi ligation buffer (TA cloning kit, Promega, UK) in a final volume of lOpl at 
4°C overnight. Competent bacteria (TopiOF', E. coli from in house stock) were 
removed  from  -70°C  and thawed  on  ice  for  5  minutes.  Two  pi  of 5%  beta- 
mercaptoethanol was added to the competent bacteria together with 2 pi of the 
ligation reaction, incubated on ice for 20 min and subsequently placed at 42° C 
for  30  seconds.  Transformed  bacteria  were  then  placed  in  SOC,  then  were 
shaken at 37°C, 225rpm for 60 minutes.
During this period the LB-agar/ampicillin petri dishes were removed from 4°C 
and coated  with 40pl  (lOOmM)  isopropyl-1-thio-P-D-galactoside  (IPTG),  and 
20pl  (50mg/ml)  5-bromo-4-chloro-3-indolyl-p-D-galactoside  (X-Gal).  After 
incubation  at  37°C  for  60  minutes,  100  pi  of  transformed  bacteria  were 
aliquoted to  individual X-Gal/IPTG/ampicillin/LB-agar petri  dishes.  The petri 
dishes were then inverted and placed at 37°C overnight.
Selection principle:  The TA cloning system involves plasmids that have been 
engineered to  contain a multiple  cloning  site  (MCS)  which has  a  lac-Z  gene 
attached. If DNA (the fragment being incorporated) ligates successfully into the 
MCS,  the  lac-Z  gene  is  disrupted,  and  the  host  bacteria  appear  as  white 
colonies,  whereas  a  functional  Lac-Z  gene  will  produce  beta-galactosidase 
which  produces  blue  colonies.  Transformed  clones  (white  colonies)  were 
picked with a pipette tip and dipped into a PCR master mix containing all the 
reagents for the PCR.  PCR was performed as described above directly on the
29bacteria and clones  containing the  ITDs  were  identified by running the  PCR 
product on an agarose gel. Mutant clones were sequenced as described above.
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3.1  Introduction
The past twenty to thirty years have seen significant improvements in therapy 
for AML such that complete remission (CR) can now be achieved in about 80% 
of  adult  patients  under  the  age  of  55  years.  (Grimwade  et  al,  1998)  This 
achievement is mainly related to the intensification of post-remission treatment 
and  advanced  supportive  care  of critically  ill  patients.  For  example,  in  the 
United Kingdom Medical Research Council (MRC) trials for the treatment of 
AML,  a  progressive  improvement  in  survival  has  been  observed  in  3 
consecutive studies carried out over the last 18 years. In the MRC AML 9 trial 
completed in  1990, the  overall  survival  (OS)  in patients  below the age  of 60 
years  induced  by  DAT  3+10  (daunorubicin  for  3  days,  cytarabine  and  6- 
thioguanine for 10 days) was 25% at 10 years (Rees et al,  1996). In contrast, in 
the more recent MRC AML  12 trial for patients below the age of 60 years of 
age, which recruited a total of 3,459 patients over 7 years, the OS had nearly 
doubled to 45% at 5 years (Burnett et al, 2003). However, despite this progress, 
relapse remains a major cause of failure in a substantial number of patients, and 
approximately  50%  will  relapse  and  die  from  their  disease.  Therefore,  to 
improve survival further, it will be necessary to identify those patients who are 
at  increased  risk  of relapse,  and  to  determine  more  appropriate  therapy  for 
them.
Certain  biological  markers  such  as  age,  WBC  at  presentation,  antecedent 
myelodysplasia (MDS), lactate dehydrogenase (LDH) levels, expression of the 
multiple drug resistance (MDR) phenotype, karyotype, and response to course 
1   of induction chemotherapy have been used over the years to identify patients 
at increased risk of relapse (Buchner et al,  1999; Wheatley et al,  1999). Among 
them,  cytogenetic  abnormalities  have  emerged  as  an  independent  prognostic 
factor, predicting not only those patients who are likely to achieve CR but also 
those  who  are  at risk of relapse  (Grimwade  et al,  1998;  Slovak  et al,  2000). 
Apart  from  their  predictive  value  in  disease  outcome,  cytogenetics  have
31significantly  increased  our  knowledge  of  the  basic  genetic  mechanisms 
involved in the process of leukaemogenesis.
Three major cytogenetic risk groups have been proposed and integrated into a 
prognostic  index  applicable  in risk-directed therapy.  Patients  with favourable 
cytogenetic disease  [i.e. t(8;21), t(15;17), inv(16)]  are not recommended for a 
BMT in CR1  and long-term disease free survival (DFS) can be achieved with 
chemotherapy alone (Burnett et al, 2002). In patients with poor risk disease as 
defined  by  the  MRC  group  [i.e.  -7,  -5,  del(5q),  3q  abnormalities,  complex 
karyotype with more than 4 unrelated abnormalities], the  survival rate is less 
than 20% and these patients are considered candidates for more aggressive or 
experimental treatment (Grimwade et al,  1998).  Between these two groups, a 
high proportion of newly diagnosed AML patients (approximately two thirds) 
are  classified  as  having  standard or intermediate  risk  disease.  These  patients 
have  either normal cytogenetics  or abnormalities that are  not  included  in the 
definition  of the  other  subgroups  [i.e.  +8,  llq23,  +21,  del(7q),  del(9q),  +22 
(according to the MRC  classification)]  (Grimwade et al,  1998).  Although the 
remission rate in this group of patients is similar to that observed in favourable 
risk disease,  the  relapse  risk  is  in excess  of 50%.  Moreover,  they  lack  other 
biological  or  molecular  markers  that  discriminate  them  as  “carriers”  of that 
risk.  Therefore,  additional  prognostic  factors  are  required,  in  particular  to 
identify those patients with standard risk disease who are at risk of relapse.
As  the  clinical  value  of  intensive  protocols  and  high  dose  chemotherapy 
followed  by  stem  cell  transplant  has  now  been  firmly  established,  thorough 
understanding  of the  individual  prognostic  factors  has  become  of significant 
importance  for treatment choice when therapeutic decisions have to be taken. 
For example, it was not uncommon some years ago to transplant patients with 
t(8;21)  in  CR1,  but  this  option  can  now  be  reserved  for  those  patients  who 
might relapse (Burnett, 2002). Similarly, in the future, one may anticipate that 
the emergence of genetically defined subgroups within patients with standard 
risk disease may differentiate between those who will need a BMT in CR1  and 
those who will need to save such approach for subsequent relapses.
32Recently,  the  emergence  of  FLT3  mutations  as  potential  independent 
prognostic  factors  in  AML  has  generated  much  interest  at  the  clinical, 
molecular and possibly therapeutic level.
3.2  FLT3
FLT3  (fms-like tyrosine  kinase  3), also known as  stem  cell tyrosine kinase-1  
(STK1) or fetal liver tyrosine kinase-2 (FLK-2), is one of the Class III tyrosine 
kinase  (TK)  receptors  that  share  sequence  homology  and  structural 
characteristics.  The  latter  include  five  immunoglobulin-like  domains  in  the 
extracellular  region,  an  intracellular juxtamembrane  (JM)  domain,  two  TK 
domains interrupted by a kinase insert, and a C-terminal tail (Agnes et al, 1994) 
(Figure  3.1).  The  gene  is  located  at  chromosome  13ql2  and  consists  of 24 
exons  (previously  reported  as  21)  (Rosnet  et  al,  1991;  Abu-Duhier  et  al, 
2001a).
FLT3 is predominantly expressed on haemopoietic progenitor cells in the bone 
marrow,  thymus  and lymph nodes  (Rosnet et al,  1993),  but  is  also  found on 
other  tissues  such  as  placenta,  brain,  cerebellum  and  gonads  (Maroc  et  al, 
1993).  Interaction  with  its  ligand  (FL)  results  in  receptor  dimerization, 
autophosphorylation, and subsequent phosphorylation of cytoplasmic substrates 
that  are  involved  in  signalling  pathways  regulating  the  proliferation  of 
pluripotent  stem  cells,  early  progenitor  cells  and  immature  lymphocytes 
(Lyman,  1995).  This  interaction is  influenced by other cytokines  such  as Kit 
ligand (KL).  In fact, when primitive human progenitor cells  are  stimulated in 
vitro with either FL or KL alone they show little or no proliferative response, 
but both ligands together synergistically enhance growth (Hannum et al,  1994). 
Further evidence for the importance of FLT3  in early haemopoiesis has come 
from  FLT3  knockout  mice.  They  are  healthy  with  normal  peripheral  blood 
counts, but they have reduced numbers of bone marrow early B-cell precursors, 
plus  a  defect  in  primitive  cells  as  measured  by  long  term  competitive 
repopulation  assays  and  a  reduced  ability  to  reconstitute  B-cell,  T-cell  and 
myeloid  lineages  when transplanted  into  irradiated hosts  (Mackarehtschian et 
al, 1995).
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Figure 3.1 Schematic representation of the functional domains of FLT3
3.2.1  FLT3 expression in leukaemias
Expression  of FLT3  has  been  reported  at  the  mRNA  and/or  protein  level  in 
93% of AML patients, 87% of T-cell acute lymphoblastic leukaemia (ALL) and 
up to  100% of B cell ALL patients (Drexler,  1996). It has not been detected in 
chronic myeloid leukaemia in chronic phase but appears to be highly expressed 
during disease transformation, irrespective of the phenotype (Birg et al,  1992). 
In leukaemic cell lines it is expressed in approximately 90% of pre B cell lines, 
but less frequently (40% - 80%) in myeloid and monocytic cell lines (Drexler, 
1996).  Studies  have  also  demonstrated very high  levels  of FLT3  mRNA  and 
protein in AML patients, leading to the suggestion that its over-expression may 
play  a role  in the  survival  and  proliferation of leukaemic  cells  (Carow et al, 
1996). This is in line with the finding that FL can induce proliferation in some 
FLT3-expressing primary leukaemic cells and cell lines (Dehmel et al,  1996). 
Furthermore,  chronic exposure of mice to FL by transplantation with primary 
haemopoietic  cells  constitutively  expressing  the  FL  gene  has  been  shown  to 
induce  leukaemia  with  a  long  latency period,  indicating  a possible  autocrine 
mechanism  for maintaining the  survival  of a  leukaemic  clone  (Hawley  et al, 
1998).
343.3  FLT3 mutations
3.3.1  Internal tandem duplications (ITDs)
The first FLT3 mutations to be identified were serendipitously detected during 
an investigation into the incidence and distribution of FLT3 mRNA in samples 
from  adult  AML  and  childhood  ALL  patients  (Nakao  et  al,  1996). 
Unexpectedly long fragments were detected in PCR products of the JM domain 
in 5 out of 30 AML patients. They were also found using genomic DNA from 
the  same  patients,  excluding  the  possibility  of aberrant  alternative  splicing. 
Further  analysis  showed  that  they  all  contained  a  tandemly  duplicated 
sequence,  sometimes  with  insertion of additional  nucleotides.  The  duplicated 
region was variable in both size and location in different individuals but always 
fell within the JM domain encoded by exons  14 and  15 (previously 11  and  12) 
(Abu-Duhier et al, 2001a).  The resulting transcripts were always in-frame and 
would therefore be expected to produce functional FLT3 chains (Figure 3.2).
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Figure 3.2 Schematic representation of FLT3 and FLT3/ITD activating mutations
35Preliminary in vitro analysis of FLT3/ITDs transfected into Cos7 cells showed 
that  they  induced  ligand-independent  receptor  dimerization  and 
phosphorylation, irrespective of the location and length of the ITD, and led to 
phosphorylation of wild type (WT) FLT3 expressed in the same cell (Kiyoi et 
al,  1998).  They  have  been  shown  to  confer  growth  factor  independence  on 
factor-dependent  cell  lines  such  as  Ba/F3  and  32D  cells,  and  to  induce 
constitutive  activation  of downstream  signalling  molecules  such  as  STAT5, 
MAP kinase, Akt, SHC, CBL, VAV and SHP2 (Hayakawa et al, 2000; Mizuki 
et  al,  2000;  Tse  et  al,  2000;  Kiyoi  et  al,  2002).  However,  comparable 
constitutive activation is not always observed in primary leukaemic blasts.  Of 
27  AML  samples  studied  by  Fenski  et  al  (2000),  18  had  ligand-dependent 
FLT3 phosphorylation and 3 of these had a FLT3/ITD. Conversely, 3 samples 
had constitutive FLT3 phosphorylation, but only  1   had a FLT3/ITD. Similarly, 
Birkenkamp  et  al  (2001)  reported  that  of  12  samples  with  both  FLT3  and 
STAT5 constitutive phosphorylation, only 8 had a FLT3/ITD, and of 5 samples 
with constitutive STAT5 but not FLT3 phosphorylation, 2 had a FLT3/ITD. It 
is likely that,  at least to some extent, these results indicate the redundancy of 
signalling pathways within the cell, and the multiple ways in which they can 
become activated.
A  striking  feature  of  the  FLT3/ITDs  identified  in  AML  patients  is  their 
diversity,  in  both  size  and  location.  In  general  the  length  of the  duplication 
varies between  12 and 204 bps but it has been reported to be as short as 3 bps 
and as long as >400bps (Schnittger et al, 2002). Most ITDs occur at the 5' end 
of the JM domain, in exon 14, and the TK1  domain is minimally involved, but 
they  differ  in  the  precise  sequence  duplicated  and  its  starting  point.  Several 
inserted sequences of unknown origin varying between 9 and 36bps have also 
been  detected  (Kiyoi  et  al,  1998;  Frohling  et  al,  2002;  Thiede  et  al,  2002). 
There  is  no  sequence  which  is  common to  all  reported  duplications,  but the 
involved region does contain a tyrosine-rich stretch of sequence and most ITDs 
include at least  1   of the tyrosines 589, 591, 597 or 599 which form part of the 
motifs  YFYV  and  YEYDLK.  Since  the  latter  are  homologous  to  auto­
phosphorylation sites in the JM domains of other TK receptors, e.g. the platelet 
derived  growth  factor  p  receptor (PDGFpR),  it was  initially thought that the
36mechanism by which duplication might lead to enhanced growth was through 
the  gain  of additional  SH2  binding domains  (Yokota et al,  1997).  However, 
neither  substitution  of  all  4  tyrosines  with  phenylalanine,  nor  deletion  of 
between 1  (AY599) and 4 (AY589-599) tyrosines, alters the in vitro constitutive 
phosphorylation  state  and  ability  to  induce  growth  factor  independence  of a 
FLT3/ITD, although these residues are clearly important for ligand-dependent 
activation  of the  WT  receptor  (Kiyoi  et  al,  2002).  Instead,  current  models 
suggest that the JM domain has a negative regulatory role which is disrupted by 
the ITD  elongation (Gilliland & Griffin, 2002; Kiyoi et al, 2002).  In the WT 
receptor,  the  JM  domain  takes  up  an  a-helical  conformation  which  blocks 
activation  of  the  kinase  and  may  inhibit  self-dimerization.  Ligand  binding 
overcomes  the  inhibitory  effect  by  inducing  a  conformational  change  and/or 
phosphorylation of key tyrosine residues. The ITDs may therefore prevent the 
protective  association between JM  domain and kinase,  exposing the  latter to 
constitutive activation.  They may  further allow recruitment of molecules that 
could stabilize this conformation or alter downstream signalling.
The  in vivo tumourigenic potential of a FLT3/ITD has been demonstrated by 
injection of 32D cells carrying a FLT3/ITD into syngeneic mice, which led to 
rapid  development  of  a  leukaemia-like  disease  (Mizuki  et  al,  2000). 
Furthermore, AML cells with an ITD showed an increased ability to repopulate 
bone marrow in NOD/SCID mice  (Rombouts et al, 2000).  Transplantation of 
bone marrow cells retrovirally transduced with FLT3/ITDs into recipient mice 
led to an oligoclonal myeloproliferative disorder, but, this was not sufficient to 
cause  leukaemia  (Kelly  et  al,  2002a).  However,  retroviral  transduction  of 
FLT3/ITD into bone marrow cells obtained from PML/RARa transgenic mice 
results  in  a  short  latency  acute  promyelocytic  leukaemia  like  disease  with 
complete  penetrance,  suggesting  that  FLT3  signaling  can  cooperate  with 
PML/RARa  to  give  the  complete  differentiation  block.  This  indicates  the 
requirement  for  additional  co-operating  mutations  for  a  fully  transformed 
phenotype in this model. (Kelly et al, 2002b).
It can be hypothesized that in such murine models only '2 hits' are required to 
generate leukaemia, the mutation in the transcription factor (e.g. PML/RARa)
37producing  a  block  in  differentiation  and  the  mutant  growth  factor  receptor 
providing  a  proliferative  or  survival  signal  (Deguchi  &  Gilliland,  2002). 
Interestingly,  three  recent  publications  have  presented  data  suggesting  that 
FLT3/ITD mutations may also contribute to a block in differentiation. Firstly, 
expression of a FLT3/ITD in 32D cells inhibited the G-CSF induced expression 
of  myeloid  maturation  markers  such  as  myeloperoxidase,  lysozyme  and 
C/EBPe (Zheng et al, 2002).  Secondly, microarray expression analysis of 32D 
cells  transfected  with  either  (WT)  or  ITD  FLT3  demonstrated  that  certain 
markers associated with myeloid differentiation, e.g. PU-1  and C/EBPa, were 
suppressed  in  FLT3/ITD  expressing  cells  (Mizuki  et al,  2003).  Evidence  of 
suppression of C/EBPa has come from the use of FLT3 inhibitors, where, the 
ability of the FLT3  tyrosine kinase inhibitor CEP-701  to restore  induction of 
C/EBPa expression in 32D/FLT3/ITD cells in response to G-CSF indicates that 
the  suppression  of  C/EBPa  depends  on  the  tyrosine  kinase  activity  of 
FLT3/ITD  (Zheng  et  al,  2004).  It  should  be  noted,  however,  that  reduced 
differentiation is frequently a feature of an increased proliferation rate.  In the 
FDCP-mix cell line, for instance, high concentrations of IL-3 block or reduce 
the  usual  differentiation  induced  by  other  growth  factors  (Heyworth  et  al, 
1990).
3,3.2  Mutations in the second tyrosine kinase domain (TKDs)
Mutations at aspartic acid 835 (D835) and isoleucine 836 (1836) in exon 20, in 
the second TK domain, were first independently identified in AML patients by 
Yamamoto et al (2001) and Abu-Duhier et al (2001b). They include at least 6 
different  substitutions  within the  D835  codon  leading  to  missense  mutations, 
predominantly  tyrosine  and  histidine,  less  frequently  valine,  glutamate  and 
asparagine, and mutation of 1836 to methionine (Figure 3.3). Complete deletion 
of 1836, insertion of nucleotides, and complex changes have also been detected, 
but the sequence always remains in frame. Occasional cases have been reported 
in ALL (2.8%) and MDS (3.4%) (Yamamoto et al, 2001). The mutations were 
found  to  cause  constitutive  tyrosine  phosphorylation  of  the  receptor  when 
transfected  into  Cos  7  cells,  and to  confer IL-3  independent  growth  on  32D
38cells,  indicating their gain-of-fimction property  (Yamamoto  et al,  2001).  The 
amino  acids  are  part  of the  activation  loop  which  blocks  access  of ATP  and 
substrate to the kinase domain when the receptor is in an inactive state. Ligand- 
induced activation leads to phosphorylation within the loop causing it take up 
an  active  configuration  and  allow  kinase  activity.  The  TKD  mutations  are 
thought to mimic the latter by interfering with the inhibitory effect of the loop, 
resulting  in  constitutive  kinase  activation.  Their  effect  is  therefore  similar to 
that of FLT3/ITD mutations in disrupting the auto-inhibitory mechanisms that 
normally protect the cell from unregulated signalling through FLT3.  However, 
possible  differences  in  the  functional  consequences  of  the  various  TKD 
mutations have not been investigated.
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Figure 3.3 Schematic representation of FLT3 and  FLT3/TKD activating mutations
3.3.4  Additional mutations in the second tyrosine kinase domain (TKDs)
A further constitutively activating FLT3 mutation in exon 20 has been reported 
by Spiekermann et al (2002) who detected an additional  6 bps  leading to the 
insertion of glycine  and  serine between amino  acids  840  and  841  in 2  out of 
359 (0.5%) de  novo  AML patients.  Functional  analysis  demonstrated that the 
mutant  receptor  was  constitutively  phosphorylated  and  induced  factor
39independence in Ba/F3 cells. Like the D835/I836 mutations, it is probable that 
this mutation also interferes with the inhibitory role of the activation loop.
3,3,5  Novel FLT3 mutations
Novel Flt3 mutations have been reported in exon 14 ( point mutations in codon 
579, 590-91  and 592) (Stirewalt et al, 2004), in exon 16 (point mutation in the 
first  catalytic  domain)  (Piccaluga  et  al,  2004)  and  exon  20  (point  mutation, 
Y842C) (Kindler et al, 2004). However, at this time, the importance of these 
novel  mutations  remain  unknown  and  additional  studies  will  be  needed  to 
determine potential functional and clinical impact.
This chapter reports studies to determine the impact of FLT3/ITD mutations on 
clinical outcome in a large group of well-documented patients, mostly less than 
60 years of age, treated intensively in the UK MRC AML 10 and 12 trials.
3.4  Materials and methods
DNA was available from peripheral blood (PB) or bone marrow (BM) from a 
total of 854 eligible adult patients at diagnosis who had been entered into either 
the MRC AML  10 (n = 406) or AML  12 (n = 448) trials.  The DNA samples 
were  obtained  from the  UCLH DNA/RNA bank.  All  patients had karyotypic 
analysis which was performed either in local UK cytogenetic  laboratories or, 
where no such service was available, at the MRC AML trials cytogenetic centre 
at University College Hospital, London (UCLH). Of the 854 patients studied in 
total,  746 patients were  screened for FLT3/ITD  mutations  at UCLH  and  108 
patients  were  screened  by  MF  and  DB  in  Dundee.  DNA  from  PB  of  100 
haematologically normal individuals who routinely attended the antenatal clinic 
at UCLH was also studied for FLT3/ITD mutations.
403,4.1  PCR analysis of the FLT3/ITD mutation
Exons 14 and 15 (previously 11 and 12) and the intervening intron of the FLT3 
gene  were  amplified  from  DNA using previously  described primers  1  IF  (5’- 
GCAATTTAGGTATGAAAGCCAGC-3’) and 12R (5’
CTTTC  AGC  ATTTTGACGGCAACC-3 ’) (Kiyoi et al, 1998).
PCR was performed as described in Chapter 2.4. DNA from the cell line TF-1 
was  used  as  the  WT  control.  A  fragment  of 328bp  was  produced  from  WT 
alleles. A repeat analysis was carried out on all samples with an additional band 
(FLT3/ITD+).
The same primers were used to screen cDNA, but the fragment produced was 
90bps  smaller.  Semi-quantitative  PCR  was  performed  on  all  FLT3/ITD+ 
samples  as described in chapter 2.5  using the primers as above.  The  level of 
mutant FLT3 expressed as a percentage of the total signal.
3.4.2  Sensitivity and reproducibility of  semi-quantitative PCR
In order to  evaluate  sensitivity of the technique,  HL-60  cell  line  blasts with 
WT FLT3  were mixed with blast cells from a patient carrying predominantly 
ITD  alleles (94%) to create nine different mixtures containing between  100% 
and  0.01%  patient  cells  (50:50,  80:20,  90:10,  95:5,  99:1,  99.5:0.5,  99.9:0.1, 
99.95:0.05,  99.99:0.01).  DNA was  extracted and semi-quantitative PCR was 
performed  as  described  in  chapter  2.5.  Reproducibility  was  assessed  by  5 
separate analyses of 3 patient samples with high, intermediate or low level of 
mutant FLT3.
3.5  Endpoints and Statistical methods
Statistical analysis was performed by the Clinical Trial Service Unit, University 
of Oxford.  Standard MRC criteria were followed to define complete remission 
(CR),  remission  failure,  resistant  disease  (RD),  induction  death  (ID),  overall 
survival  (OS),  disease  free  survival  (DFS),  event  free  survival  (EFS)  and 
relapse risk (RR) as follows: CR was defined as a normocellular BM containing
41<5%  blasts  and  showing  evidence  of  normal  maturation  of  other  marrow 
elements. PB regeneration was not a requirement, but 97% of cases defined as 
CR  achieved  a neutrophil  count  of  1  x  109/L  and  a platelet  count  of  100 x 
109/L.  Remission  failures  were  classified  by  the  clinicians  as  either  partial 
remission (PR, defined as 5 -  15% blasts or <5% blasts but a hypocellular BM), 
resistant  disease  (RD,  >15%  blasts  in  the  BM)  or  induction  death  (ID,  i.e. 
related to  treatment  or hypoplasia).  Where  the  clinicians’  evaluation was  not 
available, deaths within 30 days of entry were classified as ID and deaths later 
than 30 days after entry as RD. OS was defined as the time from diagnosis to 
death, and EFS as the time from diagnosis to an event (either failure to achieve 
remission, death in first CR or relapse), with patients not achieving remission 
being counted  as having an event on day  1.  For patients achieving CR,  DFS 
was the time from the date of first CR to an event (death in first CR or relapse) 
and RR was the cumulative probability of relapse, censoring at death in CR.
The Wilcoxon two sample test (for continuous data), Mantel Haenszel test for 
trend (for grouped continous data) and Fisher's exact test (in 2 x 2 tables) were 
used  to  test  for  differences  in  clinical  and  demographic  data  by  FLT3/ITD 
positivity,  number  of mutations  (one  versus  two  or  more)  and  percentage 
mutation (<60% versus > 60%). Kaplan-Meier life-tables were constructed for 
survival data and were compared by means of the log rank test, with surviving 
patients  being  censored  at  1   May  1999  (AML  10  patients)  or  1   June  2000 
(AML  12 patients). A complete follow-up of all surviving patients to elucidate 
their  current  status  was  undertaken  in  May  1999  (AML  10)  and  June  2000 
(AML 12) so information on relevant events is available to the above censoring 
dates for the vast majority of patients, with the small number (n=l 1) of patients 
lost to follow-up being censored at the date they were last known to be alive. 
Median  follow  up  was  52  months  (range  11-127  months).  Odds  ratios  were 
calculated from the observed minus expected number of events  (O-E) and its 
variance  (O-E)  and odds  ratio plots were  used to  illustrate  differences  in the 
relative effect of FLT3/ITD between prognostic factor subgroups. Multivariate 
logistic  regression  analysis  with  a  logit  link  function  was  used  to  find  the 
factors most closely associated with CR rate and multivariate Cox models were 
used  to  analyse  OS,  EFS,  DFS  and  RR.  Models  were  fitted  using  stepwise 
selection,  with variables added to the model  if they had a P value  < 0.01  but
42removed if they had a P value > 0.05. Because of multiple testing, the level of 
significance was set at P = 0.01. All P values are two-tailed.
3.6  Results
3.6.1  Evaluation of  semi-quantitative PCR analysis
Sensitivity of the  method was  determined from  analysis  of mixtures  of 
cells with WT FLT3 and cells from a patient with 94% FLT3/ITD alleles.
The  mutant  could be  detected when >0.5%  of total  FLT3  (Figure  3.4). 
Quantification of the different mixtures gave results which were in good 
agreement  with  the  expected  values:  expected  47%  mutant,  observed 
48%;  19%  and  23%;  9.4%  and  12.8%;  4.7%  and  5%;  1%  and  1.4% 
respectively.  The results were also highly reproducible:  5  analyses of 3 
samples with different FLT3/ITD levels gave mean ± SD values of 94.4%
± 0.5% (range 93%-95%), 53.5% ±  1.1% (52%-55%) and  12.8% ± 0.8% 
(12-14%) respectively (Figure 3.5).
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Figure 3.4  Evaluation of the sensitivity of the PCR technique 
using different mixures of cells containing WT FLT3 and alleles 
with predominately FLT3/ITD
60
50
40
20
10
0
Expected  mutant 
Observed  mutant
50:50  80:20  90:10  95:5  99:1
Cell  mixture
Figure 3.5 Semi-quantitative PCR demonstrating good agreement between 
observed and expected level of mutant using different mixtures from cells 
carrying WT and predominately ITD alleles
3.6.2  Analysis of FLT3 gene  (exon  14 and 15)  in  haematologically normal 
individuals
44DNA  from  PB  of  100  haematologically  normal  individuals  was  studied  for 
FLT3/ITD mutations and all were found to have only WT alleles (FLT3/ITD 
negative).
3.6.3  Patients’ characteristics
Details of the patients’ age, sex, FAB type, PB white cell count (WBC) and % 
BM blasts are given in Table 3.1. The majority of patients (792/854, 93%) had 
de novo AML. Four hundred and thirty two patients were male (51%) and 422 
female (49%). Median age at entry was 41 years and only 4 patients were more 
than 60 years of age (61-63 years). The median WBC count at presentation was 
18.3x109/L, while  116 patients (14%) had >100xl09/L. The median percentage 
of bone marrow blasts at presentation was 80%.
Cytogenetic  analysis  revealed  that  242  patients  (28%)  had  favourable  risk 
disease, 434 patients (51%) intermediate risk and 79 (9%) adverse risk disease, 
as defined according to the MRC criteria. All patients were treated according to 
the MRC AML 10 and 12 protocols, details of which are given in appendix 1.
45Table 3.1 Clinical and demographic characteristics of the 854 AML 
patients studied
Total FLT3/ITD- 
(% total ITD-)
FLT3/ITD+ 
(% total ITD+)
% FLT3/ITD+ P
value
Total 854 627 227 27%
AML 10 406 (48%) 301 (48%) 105 (46%) 26% 0.7
AML 12 448 (52%) 326 (52%) 122 (54%) 27%
De novo 792 (93%) 582 (93%) 210(93%) 27% 0.9
Secondary 62 (7%) 45 (7%) 17(7%) 27%
FAB type
MO 14  (2%) 14  (2%) 0  (0%) 0% 0.02
Ml 148  (17%) 108(17%) 40(18%) 27% 1.0
M2 210  (25%) 161 (26%) 49 (22%) 23% 0.2
M3 159  (19%) 101 (16%) 58 (26%) 36% 0.004
M4 172  (20%) 121 (19%) 51 (22%) 29% 0.4
M5 81  (10%) 61 (10%) 20  (9%) 25% 0.7
M6 15  (2%) 14  (2%) 1  (<1%) 7% 0.08
M7 11  (1%) 11  (2%) 0  (0%) 0% 0.04
Bilineage 1   (<1%) 0  (0%) 1   (<1%) 0.3
RAEB-t 8  (1%) 7  (1%) 1   (<1%) 0.7
Unknown 35  (4%) 29  (5%) 6  (3%)
Sex
Male 432 (51%) 322 (51%) 110(48%) 25% 0.5
Female 422 (49%) 305 (49%) 117(52%) 28%
Age (years)
<15 5  (1%) 3 (<1%) 2  (1%) 40% 0.3
15-34 290 (34%) 222 (35%) 68 (30%) 23%
35-54 477 (56%) 342 (55%) 135 (59%) 28%
>55 82(10%) 60(10%) 22 (10%) 27%
Median 41 41 42 0.2
WBC (x109/L)
<10 300 (35%) 251 (40%) 49 (22%) 16% <0.001
10-19 132(16%) 98(16%) 34(15%) 26%
20-49 168 (20%) 125 (20%) 43 (19%) 26%
50-99 120(14%) 76(12%) 44(19%) 37%
> 100 116(14%) 63 (10%) 53 (23%) 46%
Median 18.3 14.3 38 <0.001
% BM blasts
<80% 349 (41%) 285 (45%) 64 (28%) 18% <0.001
> 80% 417(49%) 278 (44%) 139(61%) 33%
Median 80 79 87 <0.001
P values are for the Mantel Haenszel test for trend in age, WBC, % BM blasts and Fisher's 
exact test for AML 10 versus AML 12, de novo versus secondary AML and each individual 
FAB type versus all other known FAB types.
463.6.4 Overall incidence of FLT3/ITD in  854 patients and in  different FAB 
types and cytogenetic risk groups
In the total group of 854 patients, 227 (27%) had a FLT3/ITD mutation. There 
was a slight difference in the incidence observed in DNA from BM (104/330, 
32%  FLT3/ITD+)  and  PB  (103/391,  26%  FLT3/ITD+)  but  this  was  not 
significant  (p  =0.1).  FLT3/ITD  was  found  in  all  FAB  subgroups  except  MO 
(0/14,  p=0.02)  and  M7  (0/11,  p=0.04),  and  was  found  in  only  1   out  of  15 
patients  with M6  (p=0.08),  although the  numbers  of patients  in these  groups 
were small.  It was significantly more common in M3  (58/159, 36%, p=0.004) 
and  in  accord  with this  finding,  the  incidence  of FLT3/ITD  in patients  with 
t( 15; 17)  was  37%  (p=0.02).  Lower  frequencies  were  found  in  patients  with 
t(8;21)  and  inv(16),  (9%,  p=0.0004  and  7%,  p=0.003  respectively).  It  is 
noteworthy that a high frequency of mutations was  also  observed in patients 
with normal cytogenetics (34%, p=0.0001). Particularly low levels of mutations 
were  found  in  llq23  (0%,  p=0.006),  del  5q  (0%,  p=0.006)  and  complex 
karyotypes (2%, p=0.00003) (Table 3.2).
3.6.5 Clinical and biological characteristics of the FLT3/ITD+ patients
Presence  of the  mutation was  not related to  sex  or age.  FLT3/ITD+ patients 
altogether had significantly higher PB  white  cell  counts  at diagnosis  (median 
count  for  FLT3/ITD-  patients  was  14.3  x  109/L  and  for FLT3/ITD+ patients 
38.0 x  109/L, p<0.001), and this was also the case for patients with FAB type 
M3  (median  count  for  FLT3/ITD-  patients  3.3  x  109/L  and  for  FLT3/ITD+ 
patients  11.4 x  109/L,  p<0.0001).  The percentage  of BM blast cells was  also 
higher  in  the  FLT3/ITD+  patients  (median  for  FLT3/ITD-  patients  79%, 
FLT3/ITD+ 87%, p<0.001).
47Table 3.2  Incidence of FLT3/ITD+ patients in different cytogenetic risk 
groups and subgroups
Cytogenetics Total FLT3/ITD- FLT3/ITD+ %
FLT3/ITD+
P value
Favourable 242 184 58 24%
risk
t(l 5; 17) 133 84 49 37% 0.002
t(8;21) 67 61 6 9% 0.0004
inv(16) 42 39 3 7% 0.003
Intermediate 434 302 132 30%
risk
Normal 281 185 96 34% 0.0001
del(7q) 20 18 2 10% 0.1
llq23 18 18 0 0% 0.006
+8 74 53 21 28% 0.7
+22 12 10 2 17% 0.7
Adverse risk 79 73 6 8%
Complex 44 43 1 2% 0.00003
del(5q) 19 19 0 0% 0.006
-5 16 16 0 0% 0.02
-7 30 28 2 7% 0.01
abn(3q) 23 19 4 17% 0.5
Unknown 99 68 31
P values are from Fisher's exact test for each individual cytogenetic 
abnormality versus all other known karyotypes.
3.6.6  FLT3/ITD mutation and clinical outcome as determined in  univariate 
analysis
The  median  follow-up  of surviving  patients  included  in  this  study  was  52 
months, with some patients followed up for over  10 years, allowing long-term 
analysis of relapse rates and survival.
3.6.6.1  Response rate
The CR rate for the 854 patients was 82%. Details of the relationship between 
the presence of a FLT3/ITD mutation and clinical outcome, as determined by
48univariate analysis, are given in Table 3.3. There was borderline significance to 
the association between the presence of a FLT3/ITD mutation and a lower CR 
rate  (p =0.05)  and  a higher ID rate  (p =0.04),  but no  significant relationship 
with RD (p=0.4).
3.6,6.2  Survival outcome
The overall actuarial survival at 5 years from diagnosis was 41% (SE  1.8) for 
the  entire  cohort  of 854  patients.  Presence  of the  mutation  had  a  significant 
impact on survival,  including OS, EFS, DFS  and RR (Table  3.3).  The RR in 
patients  with  a  FLT3/ITD  at  5  years  was  62%  (SE  4.2)  (176  patients)  as 
opposed to 44% (SE 2.6) (524 patients) in those without the mutation (p<0.001) 
(Figure 3.6).  Similarly, DFS (Figure 3.7), EFS and OS (Figure 3.8) were 32% 
(SE  3.8)  (176 patients),  25% (SE  3.1)  (226 patients)  and  35%  (SE  3.4)  (227 
patients) respectively in patients with a FLT3/ITD as opposed to 46% (SE 2.4) 
(524 patients), 39% (SE 2.1) (625 patients) and 43% (SE 2.2) (627 patients) in 
those without the mutation (p<0.001 for all of them).
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Figure 3.6 Relapse risk in patients with and without a FLT3/ITD
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Figure 3.7 Disease free survival in patients with and without a FLT3/ITD
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Figure 3.8 Overall survival in patients with and without a FLT3/ITD
3.6.7  Multivariate analysis of outcome including FLT3/ITD as a co-variable
A  Cox  multivariate  analysis  was  performed  for  RR,  DFS,  EFS  and  OS,  the 
variables  considered  being  the  presence  of  a  FLT3/ITD  mutation,  the 
cytogenetic  risk  group  (favourable  versus  intermediate  versus  adverse), 
presentation WBC, percentage BM blasts at diagnosis, age, sex, and FAB type. 
In addition, for analyses of outcome after CR, the response status post course  1
50of induction chemotherapy was  included,  as this  parameter would  always be 
used clinically in decisions about treatment intensification.  The presence of a 
FLT3/ITD was the most significant factor adversely  affecting RR (p<0.0001, 
risk ratio 2.19) and DFS (p< 0.0001, risk ratio  1.97). For RR, cytogenetic risk 
(p<0.0001, risk ratio  1.83) and status post course  1   (p=0.001, risk ratio 2.03) 
were also relative risks, however less powerful (Table 3.4).
Table 3.3  Clinical outcome in FLT3/ITD- and FLT3/ITD+ patients
Total FLT3/ITD- FLT3/ITD+ P value
Number of patients 854 627 111
Complete remission 82% 84% 78% 0.05
Induction death 8% 7% 11% 0.04
Resistant disease 10% 9% 11% 0.4
Outcome at 5 years (with SE)
RR 49% (2.1) 44% (2.4) 62% (4.1) <0.001
DFS 42% (2.0) 46% (2.3) 32% (3.6) <0.001
EFS 35% (1.7) 39% (2.0) 25% (2.9) <0.001
OS 41% (1.8) 44% (2.1) 35% (3.2) <0.001
P values are for Mantel Haenszel test for trend for CR and reasons for failure, 
and log rank test for outcome at 5 years. Figures in parentheses are standard 
errors.
Table 3.4 Multivariate analysis of CR, RR, DFS, EFS and OS considering 
FLT3/ITD (yes or no) as the only FLT3 variable
CR RR DFS EFS OS
N=655 N=524 N=524 N=656 N=656
Cytogenetic risk 
(OR-4 78,
p<0.0001)
FLT3
(Risk R=2.19, 
p<0.000l)
FLT3
(Risk R=l.77, p<0.0001)
Cytogenetic risk
(Risk R= 1.92, p<0.0001)
Cytogenetic risk
(Risk R=l .97, p<0.0001)
AML M3
(OR=7.02,
p<0.0001)
Cytogenetic risk
(Risk R“ 1   83,
p<0.0001)
Status post course 1
(Risk R=1.97, p=0.0002)
FLT3
(Risk R=1.34, p=0.003)
Gender
(Risk R=0.76, p=0.01)
Initial WBC
(OR=0.50,
p«0.0002)
Status post course 1
(Risk R=2.03,
p=0001)
AML MO
(Risk R=l.73, p=0.001)
Gender
(Risk R=0.75, p=0.005)
Age
(Risk R=1  01, p=0.0l)
Gender
(OR=0.50,
p=0,004)
AML M3
(Risk R=0.52,
p=0.01)
Cytogenetic risk
(Risk R=1.54, p=0.001)
Initial WBC
(Risk R= 1.002, p=0.006)
FLT3
(Risk R= 1.31, p=0 03)
Age
(OR=l  03,
p=0.01)
AML MO
(Risk R=1  66, 
p=0.01)
AML M3
(Risk R=0.59, p=0.01)
Age
(Risk R= 1.01, p=0.03)
Initial WBC
(Risk R= 1.002, p=0.03)
OR: odds ratios, Risk R: risk ratios
OR and RR are given in order of most to least important
51Cytogenetic risk group was more significant than the presence of a FLT3/ITD 
for  EFS  (pO.OOOl,  risk  ratio  1.92)  and  OS  (pO.OOOl,  risk  ratio  1.97), 
reflecting  the  additional  influence  of  cytogenetics  on  the  CR  rate,  but  a 
FLT3/ITD still added prognostic information to the other prognostic factors (p 
=0.009  for  OS  and p=  0.002  for EFS).  Figure  3.9  shows  the  relapse  rate  in 
patients with or without a FLT3/ITD grouped according to risk category.  The 
Kaplan Meier curves  clearly demonstrated that  in  all  risk  categories  patients 
with a FLT3/ITD do worse compared to those without the mutation. However, 
the biggest difference in relapse rate was observed in patients with standard risk 
disease and FLT3/ITD as compared to those with standard risk disease and wild 
type  gene  (74%  versus  48%  at  5  years).  This  striking  difference  may  have 
tremendous  therapeutic  implications  as  will  be  discussed  later  on  in  this 
chapter.
Poor risk ITD+  (100%)
Poor risk ITD+  (76%) 
Standard risk ITD+ (74%)
Standard risk ITD-  (48%)
Good risk ITD+  (39%)
Good risk ITD+  (30%)
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Figure 3.9 Relapse rate in patients with or without a FLT3/ITD grouped according to
risk category
3.6.8 Level of mutant and number of FLT3/ITD mutations
Semi-quantitative  radioactive  PCR  was  carried  out  on  224  of  the  227 
FLT3/ITD+ samples. This was more sensitive than agarose gel electrophoresis
52at  separating  bands  with  small  size  differences.  Moreover,  this  technique 
allowed the relative level of the mutant to be quantified.
3.6.8.1  Number  of FLT3/ITD  mutations  in  relation  to  demographics  and 
clinical outcome
Semi-quantitative radioactive PCR showed that a significant proportion of the 
FLT3/ITD+  patients  (51/224,  23%)  had  more  than  one  FLT3/ITD  mutation 
present  (Figure  3.10).  The  majority  of these  patients  (45/51,  88%)  had  two 
mutations  but up to  four were  observed.  In most  patients  one  mutation was 
predominant  and the  other(s) were  minor components,  but  in  15  patients the 
mutations  were  present  in  approximately  equal  proportions.  There  was  a 
suggestion that patients  with two or more  mutations presented  with a higher 
WBC (median WBC for patients with one FLT3/ITD 34.4 x 109/L, two or more 
51.5 x 109/L, p=0.07) and a higher percentage of blasts in the BM at diagnosis 
(median 86% for patients with one FLT3/ITD, 90% for two or more, p=0.07) 
(Table 3.5). Patients with two or more mutations had a similar RR (64% at 5 
years, SE 8.7) to those with a single mutation (64%, SE 4.6, p=0.6). There was, 
however,  a suggestion that patients with two  or more  mutations  had a worse 
OS, 36% (SE 3.7)  at 5 years, for one mutation, 21% (SE 5.8) for two or more, 
p=0.04) (Figure 3.11). This was due to a significantly higher number of deaths 
in remission in those patients with two or more mutations (34% versus 13%, p= 
0.04), which may have occurred by chance.
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Figure 3.10 Semi-quantitative PCR of  FLT3/ITD in 12 patients with AML
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Figure 3.11  Overall survival in patients with one and two or more FLT3/ITDs
3.6.8.2  Multivariate analysis of outcome including presence of a  FLT/ITD 
and number of FLT3/ITD mutations as co-variables
Interestingly, when the number of mutations (0 versus  1   versus 2 or more) was 
added into the multivariate analysis  as well as the presence or absence of the 
mutation,  then  the  number  of  mutations  replaced  the  latter  as  the  most 
important  independent  variable  predicting  for RR  (pO.OOOl,  risk  ratio  1.86) 
and  DFS  (pO.OOOl,  risk  ratio  1.59).  In  addition,  the  number  of mutations
54became the second most important factor predicting for EFS  (p= 0.0007, risk 
ratio  1.32) and OS (p =0.0007, risk ratio  1.27), with cytogenetic risk being the 
most  important  factor predicting  for EFS  (p<0.0001,  risk ratio  1.92)  and  OS 
(pO.OOOl, risk ratio 1.98).
3.6.8.3  Relative  level  of mutant  in  relation  to  demographics  and  clinical 
outcome
The level of mutant detected relative to WT varied between 0.5% and 97% of 
total  FLT3  signal  (Figure  3.10).  From  previous  evaluation  of  the  relative 
intensity of X-chromosome alleles using a similar technique, it was found that 
the proportion of signal from one allele where there are two equally represented 
alleles was 54% ± 4% (Gale et al, unpublished observations). A technical cut­
off of 60% (50% ± 2SDs) was therefore used to represent the presence of two 
abnormal alleles in a cell or the presence of a single mutant allele plus deletion 
of the  other  allele  in  at  least  some  cells.  Most  patients  (201/224,  90%)  had 
<60% mutant.  In a significant proportion of patients  (59,  26%) the  level was 
consistent with a heterozygous mutation in all or the majority of cells, i.e. 40 - 
60%  mutant  (Figure  3.12).  However,  in  23  patients  (10%)  there  was >  60% 
mutant,  suggesting  bi-allelic  mutation  or  loss  of  WT  alleles.  This  was 
associated with an older age at diagnosis: the median age at presentation in the 
group with <60% mutant was 42 years and with > 60% mutant 49 years, p=0.04 
(Table 3.5). It was also associated with leukocytosis: median WBC at diagnosis 
was 35.2 x 109/L with <60% mutant, 63 x 109/L with > 60% mutant (p=0 .03), 
poorer cytogenetic  risk  group (p=0.03)  and with FAB  type  M4  (p=0.02).  No 
patients  with  >  60%  mutant  had  FAB  type  M3  (p<0.001).  There  was  no 
difference in achievement of CR in the two groups, but there was a suggestion 
of worse outcome in patients with > 60% mutant, with a marginally increased 
RR in this  group  [85% (SE  11.9) versus 62% (SE 4.3) at 5  years,  (p =0.06)] 
(Figure 3.13). When the percentage mutation (0% versus <60% versus > 60%) 
was added as a parameter to the multivariate analysis that already included the 
number of mutations, then no further prognostic information was obtained.
55Table 3.5 Clinical and demographic characteristics of patients grouped according the 
number of FLT3/ITDs and the relative level of mutation
One
FLT3/ITD 
(% of total 
with 
one
FLT3/ITD)
More than one FLT3/ITD 
(% of total with more than one)
P
value
<60% FLT3/ITD 
(% of total with <60%)
>60% FLT3/ITD 
(% of total with >60%)
P value
Total 173 51 201 23
FAB type
Ml 31  (18%) 8(16%) .8 33(16%) 6 (26%) .3
M2 35 (20%) 14(27%) .2 44 (22%) 5 (22%) 1.0
M3 45 (26%) 12(24%) 9 57 (28%) 0(0%) .0008
M4 39 (23%) 11 (22%) 1.0 40 (20%) 10(43%) 02
MS 17(10%) 3 (6%) .6 18(9%) 2 (9%) 1.0
M6 1   d%) 0 (0%) 1.0 1  (1%) 0 (0%) 1.0
Cytogenetic risk group
Favourable 44 (25%) 12(24%) .3 56 (28%) 0 (0%) .03
Intermediate 105 (61%) 27 (53%) 116(58%) 16(70%)
Adverse 2(1%) 4(8%) 6(3%) 0 (0%)
Unknown 22(13%) 8(16%) 23(11%) 7 (30%)
Age at entry
<15 1   (1%) 1  (2%) .8 2(1%) 0 (0%) .5
15-34 50 (29%) 15(29%) 61  (30%) 4(17%)
35-54 105 (61%) 30 (59%) 117(58%) 18(78%)
255 17(10%) 5(10%) 21  (10%) 1   (4%)
Median 43 41 .3 42 49 .04
WBC (xlO’/L)
<10 40 (23%) 7(14%) I 46 (23%) 1   (4%) .3
10-19 29(17%) 5(10%) 31  (15%) 3(13%)
20-49 32(19%) 10(20%) 38(19%) 4(17%)
50-99 32(19%) 12(24%) 34(17%) 10(43%)
2100 39 (23%) 14 (27%) 48 (24%) 5 (22%)
Median 34.4 51.5 .07 35.2 63.0 .03
% BM blasts
<80% 54 (31%) 10(20%) .2 56 (28%) 8 (35%) .6
104(60%) 33 (65%) 123(61%) 14(61%)
>80%
Median 86 90 .07 86 87.5 .5
Sex
Male 80 (46%) 28 (55%) .3 102(51%) 6 (26%) .3
Female 93 (54%) 23 (45%) 99 (49%) 17(74%)
P values are Mantel Haenszel test for the trend in cytogenetic risk, age, WBC, % BM blasts and 
Fisher's exact test for each individual FAB type versus all other known FAB types.
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Figure 3.12 Level of mutant FLT3/ITD  (% of total FLT3)
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Figure 3.13 Overall survival according to the mutant level of FLT3/ITD mutation
3.7  Discussion
At the time this work was initiated, 2 studies had been published showing the 
prognostic  significance  of a FLT3/ITD mutation in adult patients with AML. 
The  first  report  by  Kiyoi  et  al  (1999)  of  201  adult  patients  with  newly 
diagnosed  AML  except  M3,  showed that  the  incidence  of a  FLT3/ITD  was 
22.8%  and  demonstrated,  in a multivariate  model  analysis,  that  a  FLT3/ITD 
was an independent prognostic factor predicting for OS  in patients below the 
age of 60 years. The second study a year later by Rombouts et al (2000) of 81 
patients  with  AML  confirmed  the  increased  relapse  risk  in  patients  with 
FLT3/ITD, indicating the prognostic importance of this mutation.
The  present  study  was  conducted  on  a homogeneous  group  of adult patients 
below the age of 60, where 93% of patients had de novo AML and were treated 
with 2 similar protocols according to the UK MRC  10 and 12 trials. It aimed to 
explore  possible  associations  of the  mutation  with  adverse  clinical  outcome, 
and at the same time to look at the biological, molecular and clinical features 
associated with the mutation. The incidence of FLT3/ITD mutations was found 
to be 27%, which was marginally higher than that found in the Japanese (23%) 
(Kiyoi  et  al,  1999)  and  Dutch  (22%)  (Rombouts  et  al,  2000)  studies.  It  is
57possible  that  all  studies  based  on  DNA  banks  slightly  overestimate  the  true 
incidence of FLT3/ITD mutations as there may be a bias towards availability of 
DNA from patients with higher peripheral WBC.  In addition,  19% of patients 
had FAB  type  M3,  which had the  highest  incidence  of FLT3/ITD  mutations 
(36%) of any FAB type. Indeed, the proportion of M3 cases in this study (19%) 
slightly  exceeds  the  expected  incidence  of  about  15%  in  this  age  group, 
reflecting the thoroughness of DNA collection in this disease subtype. Despite 
these  minor  reservations,  it  is  clear  that  FLT3/ITD  mutations  are  the  most 
common single mutation described in AML to date.
Certain  biological  and  clinical  features  associated  with  the  presence  of  a 
FLT3/ITD  were  identified.  The  incidence  of  the  mutation  varied  across 
different  FAB  types  with  the  highest  incidence  found  in  AML  M3  (36%, 
p=0.004).  Conversely,  a  low  incidence  was  observed  in  AML  M6  (1/15 
patients,  p=0.08),  although  the  number  of  patients  studied  was  small. 
FLT3/ITD positive cases were not found either in  14 patients with AML MO 
(p=0.02)  or  in  11  patients  with AML  M7  (p=0.04).  The  significance  of this 
variation among different FAB types remains obscure and no explanation can 
be given why the mutation occurs more frequently in certain FAB types and not 
others.  Nevertheless,  the  most  interesting  variation  in  the  frequency  of the 
mutation  was  found  in  different  cytogenetic  abnormalities.  High  incidence 
(37%)  was  observed  in  patients  with  t(l5; 17)  while  the  frequency  in  core 
binding  factor  leukaemias  was  low,  9%  and  7%  in  t  (8;21)  and  inv(16) 
respectively.  High  incidence  was  also  found  in  patients  with  normal 
cytogenetics  (34%)  and  in  patients  with  standard  cytogenetic  risk  disease 
(30%), as defined by MRC criteria (p=0.0001  for both). This observation may 
have  important  clinical  implications  as  patients  with  standard  risk  disease 
represent  1/3  of newly  diagnosed  cases  of AML.  Furthermore,  the  lack  of 
additional  prognostic  factors  in  this  group  of  patients  may  well  define 
FLT3/ITD+  patients  as  a  distinct  subgroup  with  adverse  clinical  outcome, 
where  more  intensive  treatment  may  be  needed  compared  to  FLT3/ITD- 
patients.
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incidence of FLT3/ITD mutations in adult, paediatric and elderly patients with 
AML  (Table  3.6).  Several  additional  studies  have  been  reported  in  abstract 
form.  The results appear relatively diverse, as certain factors such as age and 
cytogenetic  risk  subgroup  differ  from  study  to  study.  For  example,  the 
incidence of the mutation in adult patients ranges from  13% to 34%. However, 
there are a number of common features which are evident in most studies. The 
incidence  of  the  mutation  is  higher  in  patients  with  t(15;17),  normal 
cytogenetics and standard risk disease, and significantly lower in patients with 
core binding factor leukaemias and poor risk cytogenetics. In paediatric patients 
the incidence varies between 4.3% and  16.5% and there is a trend to increase 
with age as it has been demonstrated in 2 different studies (Zwaan et al, 2003; 
Liang et al, 2002). Finally, incidence of 33.6% and  18% has been reported in 
elderly patients with AML (Stirewalt et al, 2001; Andersson et al, 2004).
The  presence  of  a  FLT3/ITD  mutation  was  not  found  to  predict  for  the 
attainment  of CR,  which  is  in  accord  with  the  study  by  Kiyoi  et  al  (1999), 
although not the Dutch (Rombouts et al, 2000) study. The lack of effect on the 
CR  rate  may  be  because  a  FLT3/ITD  mutation  does  not  significantly  affect 
chemosensitivity of the majority of blast cells present at diagnosis, although it 
must be noted that as the vast majority of patients achieve CR during induction 
chemotherapy,  any  subtle effects  on chemosensitivity might not be  clinically 
apparent as determined by the CR rate. Subsequently, the lack of effect on CR 
rate has been confirmed in most studies in adult patients with AML. In contrast, 
almost every paediatric study has shown FLT3/ITD to affect adversely the CR 
rate (Kondo et al, 1999; Meshinchi et al, 2001; Zwaan et al, 2003).
The presence of a FLT3/ITD mutation did, however, have a major impact on 
long-term outcome in the cohort of 854 patients studied. In particular, it was the 
most  important  factor predicting  for relapse  from  CR  (p<0.0001),  and  in the 
presence  of a FLT3  mutation the  actuarial  RR at  5  years was  64%  (SE  4.1), 
compared to 44% (SE 2.4) in patients without a mutation. The relative effect of 
FLT3/ITD  on  RR  was  not  found to  differ  significantly between risk  groups.
59Table 3.6 Incidence and frequency in different cytogenetic subgroups in 
adult and paediatric AML patients with a FLT3/ITD mutation
Age  No. of patients Incidence
of
FLT3/ITD
(%)
Frequency in different cytogenetic 
subgroups
Reference
Unspecified  201 22.8 Kiyoi et al (1999)
74 (all M3) 20.3 Kiyoi et a /(1997)
90 (all M3) 37.0 Noguera el al (2002)
979 20.4 t(8;21): 5% Thiede etal (2002b)
inv(16):2.7%
t(15;17): 31%, P<0.001
Normal karyotype: 29.6%, P<0.001
t(6;9): 90%, P=0.01
Complex karyotype: 2.2%, P<0.001
1003 23.5 t(8;21): 8.7%, P=0.006 Schnittger et al (2002b)
Absent in inv(16), P=0.0002
t(15;17): 35.3%, P=0.01
llq23: 0.4%, P=0.006
Complex karyotype: 2.5%,
PC0.0001
100* 26.0 Kainz et al (2002)
< 60 years  81 22.2 Rombouts et al (2000)
112 20.0 Yokota el al (1997)
106 13.2 Abu-Duhier et al (2000)
82** 28.0 Whitman et al (2001)
523 23.0 t(8;21):  11% Frohling et al (2002)
inv(16): 2%
t(15;17): 39%
llq23: 7%
224** 32.0 Frohling et al (2002)
> 60 years  140 34.0 T in normal cytogenetics, P=0.0006 Stirewalt et al (2001)
109 20 Andersson et al (2004)
Children  94 5.3 Iwai et al (1999)
87 13.8 Xu et al (1999)
64 11.0 Kondo et al (1999)
91 16.5 Meshinchi etal (2001)
80 11.3 Liang et al (2002)
234 11.5 Normal karyotype: 54.5% p=0.003 Zwaan et al (2003)
1  lq23:0%, p=0.02
45 (non M3) 22.2 Arrigoni et al (2003)
29 (all M3) 34.5
* All intermediate and favourable risk disease; ** All normal karyotype
The  effect  was  most  reliably  demonstrable  in  the  intermediate  risk  group, 
whether defined by cytogenetics alone or by the  combination of cytogenetics 
and response  to  the  first cycle  of induction  chemotherapy,  which  is the very
60group  in  whom  improved  prognostic  stratification  is  most  required.  In  fact, 
when relapse risk was  analysed in patients with standard risk disease,  it was 
found to be 74% in FLT3/ITD patients as compared to 48% in those without 
the  mutation  (Figure  3.9).  Interestingly,  the  relapse  risk  in  patients  with 
standard risk disease and a FLT3/ITD was similar to that observed in patients 
with poor risk disease, suggesting the possibility of treating these patients with 
more experimental therapies. In accord with being the major factor predicting 
for relapse, the presence of a FLT3/ITD was also the major factor predicting for 
DFS  (pO.OOOl). Furthermore, it had an adverse effect on EFS  (pO.OOl) and 
OS (pO.OOl) (Figure 3.8).
Cox  multivariate  analysis  was  performed  for  RR,  DFS,  EFS  and  OS,  the 
variables  considered  being  the  presence  of  a  FLT3/ITD  mutation,  the 
cytogenetic risk group, presentation WBC, percentage BM blasts at diagnosis, 
age,  sex,  FAB  type  and  the  response  status  post  course  1   of  induction 
chemotherapy. The analysis showed that a FLT3/ITD was the most significant 
independent factor predicting for risk of relapse (p<0.0001, risk ratio 2.19) and 
for DFS  (pO.OOOl, risk ratio  1.97). This finding has now been confirmed by 
several studies, which agree that the presence of a FLT3/ITD is associated with 
increased  risk  of  relapse  and  reduced  DFS  and  EFS  (Kiyoi  et  al,  1999; 
Rombouts  et  al,  2000;  Frohling  et al,  2002).  Since  patients  with AML  who 
relapse  have  limited  chances  for  salvage,  OS  in  these  patients  will  also  be 
affected.
However,  two  studies  are  of  particular  interest  as  they  failed  to  show  a 
FLT3/ITD as an independent prognostic factor predicting for disease outcome. 
In a study of 640 patients, Thiede et al (2002)  found that, despite an increased 
RR  and  reduced  DFS,  there  was  only  a  trend  for  reduced  OS  with  an  ITD 
(p=0.09).  Similarly, Schnittger et al (2002) reported that an ITD affected EFS 
in their study of 563 patients, but not OS. The difference in outcome in these 2 
studies  may  have  been  influenced  by  a  number  of factors  such  as  the  short 
follow up of less than one year, and the heterogeneity of patients studied with 
respect to age and type of disease (de novo and secondary AML and antecedent 
MDS). They do, however, raise the possibility that different treatment regimens
61might have  contributed towards  a better outcome  in their patients,  especially 
the inclusion of very high dose cytarabine. In the present study, patients were 
treated  according  to  the  UK  MRC  protocols  with  a  cumulative  dose  of 
cytarabine  up  to  11.6g/m2,  where  in  the  2  studies  mentioned  above,  the 
cumulative  cytarabine  dose  was  up  to  8  fold  higher,  ranging  from  22.4  to 
92.8g/m  . Nevertheless, this may depend on the subgroup of AML as Frohling 
et  al  (2002)  found  that  intensive  chemotherapy,  including  post-remission 
cytarabine up to doses of 42g/m2, was of no benefit in FLT3/ITD patients with 
normal cytogenetics. This group also fared badly in the study by Boissel et al 
(2002) comparing 3 different reinforced induction regimens, although they did 
find some suggestion of drug intensification improving outcome in FLT3/ITD 
patients. It is clear that evaluation of treatment protocols during the induction or 
consolidation phase in patients with a FLT3/ITD requires further investigation, 
preferably prospective within randomised trials, in order to further refine risk- 
adapted therapy.
The observation that 23% of FLT3/ITD+ patients had more than one FLT3/ITD 
mutant of varying levels, suggests that, at least in some patients, the mutations 
were  present  in  different  clones.  Patients  with two  or  more  mutants  did  not 
have  a  significantly  higher  RR  than  those  patients  with  just  one  mutation 
(p=0.6).  Patients  with  more  than  one  mutation  had  a  significantly  higher 
mortality  in  remission (p=0.04)  and this translated  into  a marginally reduced 
EFS  (p=0.07)  and OS  (p=0.04).  The reason why patients with more than one 
FLT3/ITD should have had a higher treatment-related mortality is not known. It 
is  possible  that  patients  who  develop  FLT3/ITD  mutations  may  have  other 
defects  in  their  DNA  repair  mechanisms  and  fail  to  tolerate  the  deleterious 
effect  of  cytotoxic  chemotherapy.  Nevertheless,  this  might  be  a  spurious 
association due to the play of chance. On a multivariate model where presence 
of the mutation and the number of mutations (none, one or more than one) were 
considered as co-variables, the latter replaced the former as the most powerful 
predictor of RR and DFS. This observation is difficult to explain and a number 
of possible  explanations  can be hypothesised.  The  number of mutations  may 
have a “dosing effect” on relapse risk, exerting the greatest functional effect on 
the  small  population  of  clonogenic  cells  presumed  to  be  responsible  for
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place  in  a  cell  which has  already  acquired  a malignant  phenotype,  implying 
secondary  evolutionary  mechanisms,  that  may  develop  clones  resistant  to 
chemotherapy.  Irrespective  of  mechanism,  this  finding  will  need  further 
exploration and confirmation in order to be able to be incorporated into clinical 
practice.
In  addition  to  the  frequent  detection  of more  than  one  FLT3/ITD  mutation, 
quantitative analysis demonstrated that the level of mutant was >  60% of the 
total  FLT3  signal  in  approximately  10%  of patients  with  a  FLT3/ITD.  This 
finding implies either bi-allelic mutations or deletion of WT alleles, however, 
this  10%  value  is  undoubtedly  an underestimate,  as  the  presence  of residual 
normal cells in some samples (especially from PB) would tend to decrease the 
ratio of the mutant to WT FLT3 allele. Subsequent analysis revealed that there 
was a suggestion of higher RR in those patients with > 60% mutant (p=0.06), 
but in a multivariate analysis that already included the number of mutations, the 
presence  of >  60%  mutant  was  not  an  independent  prognostic  factor.  This 
finding  has  also  been  explored by  2  different  groups  (Whitman  et al,  2001; 
Thiede  et al,  2002).  In a study by Whitman et al (2001) of 8/23  FLT3/ITD+ 
AML cases  lacking a FLT3  WT allele (FLT ITD /‘ ) the outcome was worse as 
compared to FLT3/ITD cases carrying a WT allele (FLT ,TD/WT) (P=0.008). In 
another large study, patients with a mutant to wild type ratio of 0.78 or greater 
were  noted  to  have  a  significantly  worse  outcome  than  FLT3/ITD+  patients 
with a ratio  less than 0.78  (Thiede  et al,  2002).  The  mechanism  causing the 
altered  ratio  is  attributed  in  some  cases  to  loss  of  heterozygosity  (LOH) 
(Whitman et al,  2001) but this has not been a consistent finding. Thiede et al 
(2001)  were  unable  to detect LOH  of the  WT allele  using FISH  assays  in  9 
patients with FLT3/ITD, suggesting that an increased ITD/wild type ratio might 
be due to homologous recombination of the FLT3/ITD allele, which essentially 
creates more copies of the FLT3/ITD allele than of the wild type allele. Since a 
mutant  FLT3  in  a  mutant/WT  heterodimer  can  trans-phosphorylate  the  WT 
chain, it implies that a mutant homodimer has some gain-of function more than 
simply activating the  kinase.  Alternatively,  formation of the  homodimer may
63reflect  an  underlying  mechanism  of  genetic  instability  which  has  other 
unknown genomic consequences that may, in turn, influence clinical outcome. 
In  AML,  relapse  remains  the  principal  cause  of  treatment  failure  for  the 
majority of patients. The outcome following relapse is extremely poor and only 
a  small  fraction  of  patients  can  be  salvaged.  The  fate  of  patients  with  a 
FLT3/ITD  at presentation  who  relapse  remains  unknown.  This  study,  which 
aimed to investigate the significance of FLT3/ITD in newly diagnosed patients 
with AML, was not able to explore their outcome post relapse.
In conclusion, in this large cohort of patients, the presence of a FLT3/ITD is the 
most  common  molecular abnormality  in AML.  The  mutations  are  especially 
common in t(15;17) and patients with normal cytogenetics but relatively rare in 
core-binding  factor  leukaemias  and  those  cases  with  poor  cytogenetics. 
Knowledge  of how FLT3/ITD  interacts  with  other  cytogenetic  abnormalities 
might  provide  biological  insight  into  leukaemogenesis  and  clarify  the 
uncertainties of risk stratification. FLT3/ITD is an important factor predicting 
for relapse  and DFS  and is, as a consequence,  an independent risk factor for 
EFS  and  OS.  The  laboratory  test  to  identify  the  presence  or  absence  of a 
FLT3/ITD  mutation  is  simple,  quick  and  reproducible.  The  present  results 
suggest that  even further prognostic  stratification may be  achieved by taking 
into account the number of mutations and the relative ratio of the mutant and 
WT alleles. Taken together, these results suggest that FLT3 mutations confer an 
adverse outcome and this information should be used prospectively in order to 
define effective therapeutic strategies in patients with AML.
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4.1  Introduction
Despite the progress in the treatment of AML, unfortunately, in many patients a 
temporary  phase  of  clinical  remission  is  followed  by  relapse.  Indeed, 
approximately  70%  of patients  relapse,  mainly  within  the  first  2  years  of 
completion of treatment, and die of refractory disease, with the probability of 3- 
year  survival  ranging  between  8%  and  29%  (Leopold  LH  &  Willemze  R, 
2002). Chemotherapy has increased in intensity in recent years but is perceived 
to have reached the limit of toxicity. Allogeneic BMT, either human leukocyte 
antigen  (HLA)-sibling  matched  or  matched  unrelated  donor,  is  the  only 
treatment  to  offer  long-term  DFS  and  possible  cure,  however  the  increased 
toxicity associated with the procedure restricts its use to those patients who are 
young  and  fit  to  tolerate  such  approaches  (Drobyski,  2004).  Nevertheless, 
relapse remains a major cause of failure, even in those patients who receive a 
BMT and especially for those with poor risk disease features. At present, little 
is  known  about  the  kinetics  of leukaemia  relapse,  the  development  of drug 
resistance and other host factors that might affect the progression of the disease 
(Ferrant  et  al,  1997).  It  is  thought  that  in  leukaemia  the  estimated  tumour 
burden of 1012 malignant cells may still be as high as  1010 after achievement of 
CR.  This  so-called minimal residual disease  (MRD) remains morphologically 
undetectable  as  microscopic  analysis  identifies,  at  best,  a  sensitivity  of  1-5 
leukaemic  cells  in  100  normal  cells.  Considerable  effort  has  therefore  been 
directed at identifying markers that can be used to detect residual disease at an 
earlier  stage  and  lead to therapeutic  intervention before  overt haematological 
relapse occurs.  This technology is becoming increasingly applicable, not only 
during induction chemotherapy, but also during consolidation and post-BMT. 
In  clinical  practice,  MRD  evaluation  is  emerging  as  an  integral  part  of the 
modem management of patients with leukaemia.
654.2  Use of MRD in leukaemia
The first MRD studies in patients with leukaemia were carried out soon after 
antibodies for leukocyte differentiation antigens became available. Expression 
of  the  common  antigen  (CD 10)  and  terminal  deoxynucleotidyl  transferase 
(TdT) in ALL cells suggested that these antigens could potentially be used as 
markers to identify persistent leukaemia. Similarly, expression of TdT with T- 
lymphoid antigens in T-ALL allowed the use of this combination of markers to 
detect MRD in T-ALL (Janossy et al, 1980; Bradstock et al, 1981). Since then, 
several  methods  to  study  MRD  have  been  developed  and  the  most  reliable 
include  flow  cytometric  profiling  of  aberrant  immunophenotypes,  PCR 
amplification of fusion transcripts, and amplification of antigen receptor genes.
4.3  Methodologies for detecting MRD
4.3.1 Conventional cytogenetics
Karyotypic analysis at the time of diagnosis is an essential test, as it allows the 
detection of structural and numerical changes specific to the leukaemic clone. 
The identification of clonal abnormalities can also provide valuable information 
related to  disease  prognosis.  However,  its value  for the  detection of MRD  is 
limited by its insensitivity. This is due to the relatively small number of cells 
examined, inadequate chromosome morphology, and the lack of metaphases.
4.3.2 Fluorescence in situ hybridisation (FISH)
FISH is an advantageous technique compared to conventional cytogenetics due 
to its enhanced power to detect structural rearrangements which may be missed 
with standard banding methods.
It  requires  chromosome  specific  or  locus  specific  probes  and  can  detect 
aberrations  in  non-dividing  interphase  cells.  However,  the  sensitivity  of the 
technique  approaches  1%,  which  is  markedly  below  that  desired  for  MRD 
detection.
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MRD monitoring using flow cytometry is based on the observation that 
leukaemic cells frequently display aberrant phenotypic features that allow 
their  distinction  from  normal  cells.  Cells  labelled  with  a  panel  of 
fluorescent antibodies  can be detected and quantified by a fluorescence 
activated cell sorter (FACS). The advantages of flow cytometric analysis 
include  its  relatively  high  sensitivity  for  detecting  leukaemic  cells, 
ranging from  1   leukaemic cell in 100 to 10,000 normal cells, its ability to 
analyse a large number of cells and its rapidity. However, optimisation of 
the technique requires the use of several combinations of antibodies and 
technical expertise.
4.3.4  Nucleic acid amplification techniques
Breakpoint  fusion  regions  of chromosomal  aberrations,  aberrant  genes, 
and rearranged immunoglobulin and T-cell receptor genes have been used 
with  success  in  molecular  studies  of MRD.  PCR  is  highly  sensitive, 
detecting  up  to  1   leukaemic  cell  in  1,000,000  normal  cells,  however it 
remains technically demanding and susceptible to false positives due to 
contamination. Initial studies of MRD relied on the RT-PCR assay being 
either  positive  or  negative.  However,  it  has  become  apparent  that 
estimation of the level of MRD by quantitating target genes can provide a 
more  sensitive tool  for monitoring MRD.  Quantification of the  level  of 
transcripts of a target gene can be carried out either by competitive RT- 
PCR  or  the  cycle-cycle  (real  time)  techniques.  Competitive  RT-PCR 
involves  adding  a  known  amount  of PCR-amplifiable  standard  into  an 
RNA  sample  and  then amplifying  the  standard  and  target  RNAs  in  the 
same reaction. The exogenous standard and the endogenous target use the 
same  primers  for  amplification,  thus  a  competition  for  amplification 
components  including  primers,  dNTPs,  and  polymerase  ensues.  If the 
exogenous  standard  is  designed to  be  amplified  at the  same  rate  as the 
target sequence, then the ratio of products obtained from the endogenous 
and  exogenous targets  at the end  of the  amplification reflects the  initial
67ratio of target to standard. Since the amount of exogenous standard added 
to the RT-PCR is known, the amount of endogenous target in the RNA 
sample  can  be  determined.  The  real-time  PCR  system  is  based  on  the 
detection and quantitation of a fluorescent reporter (Livak et al,  1995).
This signal increases in direct proportion to the amount of PCR product in 
a  reaction.  By  recording  the  amount  of fluorescence  emission  at  each 
cycle, it is possible to monitor the PCR reaction during exponential phase 
where  the  first  significant  increase  in  the  amount  of  PCR  product 
correlates to the initial amount of target template. The higher the starting 
copy number of the nucleic acid target, the sooner a significant increase 
in fluorescence is observed.
4.4  Application of MRD in ALL
In  ALL  and  generally  in  malignancies  of  lymphoid  origin,  clonal 
rearrangements of either immunoglobulin or T-cell receptor genes are suitable 
for MRD analysis (Goulden et al, 2001). They occur in up to 90% of patients, 
can  be  detected  using  PCR  techniques,  and  reappear  at  relapse,  although 
development of secondary rearrangements has been noted in some cases (Cave 
et al,  1998). Early studies investigating the clinical relevance of MRD in ALL 
produced  conflicting  results.  This  was  largely  because  of poor  study design, 
however  prospective  blinded  studies  have  provided  much  greater  consensus, 
demonstrating conclusively the clinical significance of MRD.  In these studies, 
MRD  during  conventional  chemotherapy  was  found  to  be  an  independent 
predictor of outcome, as the presence and level of residual leukaemia correlated 
with the risk of early relapse (Cave et al, 1998). In the BMT setting in children 
with  ALL,  MRD  detection  by  PCR  amplification  of antigen  receptor  genes 
immediately before conditioning was also predictive of subsequent relapse. For 
example in the study by Knechtli et al (1998) of 39 children who underwent a 
T-cell depleted allogeneic transplant for ALL, the detection of high level MRD 
(>  than  1   leukaemic  cell  in  1000  normal  cells)  before  transplantation  was 
associated  with  0%  EFS  at  2  years,  whereas  the  EFS  for  those  who  had 
undetectable levels of MRD was 73% (pO.OOl) (Knechtli et al, 1998). In ALL 
therefore, the collective evidence for a correlation between presence of MRD
68and increased risk of relapse is very strong and several protocols have recently 
incorporated  this  knowledge  into  treatment  adapted  therapy.  For  example, 
children who remain strongly positive for MRD after induction or consolidation 
therapy may well benefit from transplantation approaches while in morphologic 
remission, rather than await overt haematological relapse and transplantation in 
2nd CR.
4.5  Application of MRD in myeloid malignancies
4.5.1 CML
The BCR/ABL oncoprotein is a constitutively activated tyrosine kinase which 
now  considered  to  be  the  principal  cause  of  the  chronic  phase  of  CML. 
Monitoring of the BCR/ABL fusion protein using approaches such as FISH or 
RT-PCR  has  been  used  to  correlate  this  marker  with  disease  status  and 
outcome,  especially  after BMT  (Serrano  et al,  2000;  Hochhaus  et  al,  2000; 
Olavarria et al, 2001).
4.5.2 AML
In AML, cytogenetic analysis, FISH, multiparametric flow cytometry and PCR 
are  currently  being  used  for  detecting  MRD.  Conventional  cytogenetics  can 
only be  used in patients with numerical and structural  abnormalities to assess 
remission  status  post  induction  chemotherapy.  An  additional  benefit  of this 
technique  is  its  ability  to  detect  the  acquisition  of new  clonal  aberrations  at 
disease progression. However, as mentioned above, the value of cytogenetics as 
marker of MRD is very limited due to the insensitivity of the technique. MRD 
monitoring using flow cytometry in AML has extensively been applied in recent 
years.  Although studies of MRD are still limited as compared to ALL, several 
studies  have  been  published  demonstrating  that  this  technique  is  a  useful 
approach for predicting  outcome  in patients with AML treated with intensive 
regimens (San Miguel et al, 1997; Venditti et al, 2000). The study of PCR based 
techniques  is  limited by the  availability of suitable  molecular markers.  Three 
molecular  markers  that  have  been used  are  the  PML/RARa  fusion  transcript
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CBFB/MYH11  from  inv(16)  (Lo  Coco  et  al,  1999;  Tobal  &  Yin  1996; 
Marcucci et al, 2001; Laczika et al, 1998). However, the qualitative detection of 
MRD does not necessarily indicate subsequent relapse (Kusec et al, 1994, Tobal 
et al,  1995) and therefore quantification of the tumour burden is necessary. For 
example, it has been shown that patients who are positive for AML1/ETO using 
sensitive RT-PCR assays can remain in morphological and clinical remission for 
many  years.  Persistence  of the  hybrid  gene  has  been  detected  not  only  in 
patients  treated  with  chemotherapy  but  also  in  recipients  of  autologous  or 
allogeneic  BMT  (Kusec  et al,  1994;  Jurlander  et al,  1996).  Nevertheless,  re­
appearance  of  the  marker,  or  persistence  at  a  certain  level  post-induction 
chemotherapy, does generally signify an increased risk of relapse (Diverio et al, 
1998; Tobal et al, 2000).
In  the  BMT  setting,  recent  studies  have  also  suggested  a  role  for  molecular 
monitoring in AML. MRD monitoring in patients who undergo an autologous or 
allogeneic  BMT  has  demonstrated  that  the  presence  of  residual  disease  3 
months post-transplant is predictive of relapse (Meloni et al,  1997; Roman et al, 
1997).  For  example,  2  cases  of APL  with  evidence  of residual  disease  post 
ABMT  were  successfully  treated  with  ATRA,  maintaining  continuous 
morphological  and  molecular remission even  after  discontinuation  of retinoic 
acid treatment (Grimwade et al,  1998b). The successful eradication of residual 
disease  in  these  patients  suggests  that  MRD  monitoring  should  be  routinely 
performed post-transplant in order to identify patients who would be suitable for 
tailored therapeutic approaches including donor lymphocyte infusion (DLI) and 
molecularly targeted strategies.
However,  to  date,  t(8;21),  t( 15; 17)  and  inv(16)  together  account  for 
approximately one quarter of adult AML patients, (Grimwade et al,  1998a) and 
therefore other markers are required to extend the potential application of MRD 
to  more  AML  patients.  Recent  studies  have  suggested  that  expression  of the 
Wilms Tumour gene (WT1) gene might be used as a marker of MRD in AML. 
Using  quantitative  analysis,  the  WT1  expression is  at  least  10 times  lower in 
normal progenitor cells compared with leukaemic cells (Inoue et al, 1996; Inoue
70et al, 1997). Several studies using a qualitative assay for WT1 in AML found no 
correlation between WT1  expression at diagnosis and achievement of CR. For 
example,  in  a  study  by  Gaiger  et  al  (1998)  of  44  patients,  there  was  no 
difference  in  the  DFS  and  OS  from  remission  between  WT1-positive  and 
negative patients  (p>0.1).  The authors  concluded that the monitoring of WT1 
gene  expression  by  qualitative  RT-PCR  during  treatment  and  CR  is  of very 
limited  value.  In  contrast,  more  recent  data  suggest  that  using  sensitive 
quantitative assays, WT1  can be used as a marker of MRD in order to predict 
patients with AML at early risk of relapse. However, the clinical use of WT1 as 
a marker  of MRD  in  AML  will  need to  be  evaluated  in  prospective  studies 
involving  large  number  of  patients.  This  knowledge  has  currently  being 
incorporated into the MRC  15 trial, where the value of quantitative monitoring 
by REAL time PCR will be assessed prospectively.
As mutations in the FLT3 gene occur in about one third of adult AML patients, 
the  studies  in  this  chapter  explored  their  suitability  as  markers  for  MRD, 
looking for the presence of ITDs and D835  alterations in paired samples from 
patients at presentation and relapse.
4.6  Materials and Methods
4.6.1  Patients
Paired PB or BM samples at presentation and first relapse were available from 
44 patients with de novo AML who were treated with protocols from the MRC 
AML  10  and  12 trials.  A further sample at second relapse was obtained from 
one patient. Eleven of these patients had AML FAB type Ml, 7 M2, 5 M3,  13 
M4, 7 M5 and  1   patient had RAEB-t. Median age at presentation was 42 years 
(range 12-61  years), and median white cell count was 50.1 x 109/L (range 0.8 - 
541  x  109/L).  DNA  samples  were  used  for  analysis  in  42  patients,  in  the 
remaining 2 patients only RNA samples were  available.  Paired DNA  samples 
from BM at presentation and first CR following induction chemotherapy were 
also  studied in  13  AML patients who all had a mutation in the  FLT3  gene at 
diagnosis.
714.6.2  Detection of mutations in the FLT3 gene
4.6.2.1 PCR analysis of the FLT3/ITD mutation
PCR  and  semi-quantitative  PCR  analysis  of  the  FLT3/ITD  mutation  was 
performed as described in Chapter 2.4, 2.5  and 3.4.1.  DNA from the cell line 
TF-1 was used as the wild type control.
4.6.2.2  PCR  analysis  of the  FLT3/D835  mutation  and  restriction  enzyme 
digestion
PCR analysis was performed as described in Chapter 2.4. Amplification of exon 
20  of  the  FLT3  gene  was  performed  using  the  primers:  19F,  5'-
CCGCCAGGAACGTGCTTG-3', and 19R, 5'-GCAGCCTCACATTGCCCC-3', 
as previously  described by Yamamoto  et al  (2001).  Amplified products  were 
digested  with  EcoRV  (Invitrogen,  UK)  for  4  hours  at  37°C,  then 
electrophoresed through 4%  agarose  gels  and visualized under UV  light with 
ethidium  bromide  staining.  D835  and  1836  amino  acids  are  encoded  by 
GATATC, which is the recognition sequence for EcoRV. In alleles containing a 
D835  or  1836  mutation the  114bp  PCR  fragment  remained  uncut  but  in  WT 
alleles it was digested to fragments of 68 and 46bps (Figure 4.1).
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Figure 4.1  Identification of a D835 m utation in a patient with AM L: The presence of the 
m utation abolishes the recognition of the cutting site by ECoRV endonuclease (GATATC), 
producing 3 size products
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4.6.3  Polymorphic marker analysis in order to confirm patients’ identity in 
samples taken at presentation and relapse
Tandemly  repeated  DNA  sequences  are  widespread  throughout  the  human 
genome  and  show  sufficient  variability  among  individuals.  These  tandemly 
repeated regions of DNA are typically classified into several groups depending 
on  the  size  of the  repeat  region.  Minisatellites  (variable  number  of tandem 
repeats,  VNTRs)  have  core  repeats  with  9-80  bp,  while  microsatellites  (short 
tandem repeats, STRs) contain 2-5 bp repeats. The variety of alleles present in a 
population is such that a high degree of discrimination among individuals in the 
population  may  be  obtained  when  multiple  STR  loci  are  examined.  Fur  the 
purpose of this study, in cases where differences were observed in the pattern of 
FLT3 mutations at presentation and relapse, 3 polymorphic markers were used 
to  confirm  that  the  DNA  samples  were  from  the  same  patient:  KB9  on 
chromosome  19, D21S270 and D21S65 on chromosome 21  (Preudhomme et al, 
2000; Horwitz et al,  1999). One primer from each pair (Table 4.1) was 32P end- 
labelled and semi-quantitative PCR performed as described in Chapter 2.5. The 
annealing  temperatures  were  58°C  for  D21S270  and  D21S65,  and  65°C  for 
KB9.  Products  were  electrophoresed  through  denaturing  polyacrylamide  gels
73(7M  urea,  6%  polyacrylamide,  crosslinker  ratio  37.5:1,  0.5  x  Tris-Borate- 
EDTA), the gels were dried and exposed to Hyperfilm (Amersham).
Table 4.1. Oligonucleotide primers used in PCR analysis
Locus Primer Sequence
KB 9 F
R
5 '-TGC  AA  AGGCTTGG  AGGGCT  GAT  G-3' 
5'-ATCTCGG  ACAACAGC  AGGCCTCG-3'
D21S270 F
R
5'-G  A  AAT  GTTTT  AAT  A  A  ATGGTGGTT  A-3' 
5 AC  A  A  A  AGTT  ATGGT  C  A  AGGGG-3'
D21S65 F
R
5'-CCG  A  A  A  ACTT  ACT  GG  AG  A  AC-3' 
5'-G  ATCATCC  AGG AATCACC  A  A-3'
4.6.4  Cloning and sequencing of PCR products
This was performed as described in Chapter 2.6 and 2.7.
4.7  Results
4.7.1 Paired presentation/remission samples
Remission samples (marrow n=9, peripheral blood n=4) from 13 patients 
who had a FLT3 mutation at presentation were studied. All  13 patients had an 
ITD, median mutant level 44% of total FLT3 (range 2% - 90%), and  1   patient 
also  had  a  D835  mutation  (D835Y).  In  remission  all  patients  lost  their 
mutation(s) confirming that FLT3 mutations are leukaemia-specific.
4.7.2 Paired presentation/relapse samples
4.7.2.1  Patients without a FLT3 mutation at presentation
Of the 24 patients  studied who had only WT FLT3  alleles  at presentation, 20 
patients remained WT at first relapse and 4 patients acquired a FLT3 mutation 
(Table  4.2).  Two  of these  patients  acquired  a  D835  mutation,  both  G  ->  T 
leading  to  substitution  of  tyrosine  for  aspartate,  and  2  patients  gained  a
74FLT3/ITD.  The  D835  mutant  accounted  for  approximately  half of the  total 
FLT3 in the samples, and in the patients with ITDs the mutant levels were 38% 
and  42%  respectively,  suggesting  that  the  majority  of cells  at  relapse  were 
heterozygous  for  the  mutant  alleles.  No  ITD  was  detected  in  presentation 
samples from the latter 2 patients using the more sensitive radioactive PCR and 
all  4  patients  had  high  blast  counts  at  diagnosis  (patients  21-24,  Table  4.2). 
These results suggested that a FLT3 mutation had not been missed at diagnosis 
and that its  acquisition at relapse was evidence  of clonal progression.  In 3  of 
these 4 patients, sufficient DNA was available at both presentation and relapse 
to study the alleles at 3 loci known to be polymorphic for repeat sequences. The 
size of the alleles was the same at presentation and relapse, confirming that the 
2 samples came from the same individual. One patient who had only WT FLT3 
alleles at presentation and first relapse acquired a FLT3/ITD at second relapse 
with a mutant level of 45%. Polymorphic markers indicated that all 3  samples 
were from the same patient.
75Table 4.2. FLT3 status and relative percentage of mutant in peripheral 
blood or bone marrow from 44 AML patients at presentation and relapse
PRESENTATION  ____   RELAPSE
No FLT3 % Sample % Blasts FLT3 % Mutant Sample % Blasts
Mutant
1 WT PB MNC 90 WT NA 76
2 WT BM 97 WT PB MNC NA
3 WT PB MNC 95 WT BM NA
4 WT PB MNC 28 WT BM 42
5 WT NA 100 WT BM 95
6 WT NA 100 WT BM 60
7 WT PB NA WT BM 85
8 WT BM 98 WT PB 52
9 WT PB 95 WT PB 80
10 WT BM 89 WT BM 96
11 WT PB 99 WT PB 99
12 WT PB 80 WT BM NA
13 WT BM 86 WT BM 60
14 WT BM 58 WT BM 90
15 WT BM 90 WT BM 87
16* WT BM 72 WT (ITD+) (45) BM (PB) 13(87)
17 WT BM NA WT BM 11
18 WT PB 78 WT BM 56
19 WT BM 90 WT BM 64
20 WT BM 90 WT BM 74
21 WT PB MNC 90 D835+ = 50 PB MNC NA
22 WT BM 87 D835+ = 50 BM NA
23 WT PB MNC 90 ITD+ 42 BM 95
24 WT BM 95 ITD+ 38 BM 95
25 ITD+ 20 PB MNC 53 WT BM 55
26 ITD+ 6 BM 88 WT BM 92
27 ITD+ 11 PB 80 WT BM 82
28 ITD+ 28 BM 94 WT BM 85
29 ITD+ 44 BM 95 WT BM 44
30 D835
i
= 50 BM 95 D835+ = 50 BM 96
31
~T
D835
i
= 50 BM 60 D835+ = 50 BM 60
32
"T
ITD+ 13 BM 55 ITD+ 16 BM 96
33 ITD+ 39 BM 51 ITD+ 39 BM 60
34 ITD+ 44 PB MNC 77 ITD+ 45 NA NA
35 ITD+ 82 BM 97 ITD+ 84 BM 92
36 ITD+ 86 BM 86 ITD+ 83 PB 93
37 ITD+ 91 PB 70 ITD+ 91 BM NA
38 ITD+ 5 BM NA ITD+ 35 PB 97
39 ITD+ 23 PB MNC 86 ITD+ 88 BM 100
40 ITD+ 25 PB 79 ITD+ 50 PB 99
41 ITD+ 26+2 BM 90 ITD+ 56+14 BM 94
42 ITD+ 28 +3+1 BM 80 ITD+ 41 BM 99
43 ITD+ 40 PB MNC 88 ITD+ 69 PB MNC NA
44** ITD+ 44 BM 89 ITD+ 60 PB NA
MNC indicates mononuclear cells; BM, bone marrow; PB, peripheral blood; NA, not available 
* Information in brackets relates to second relapse 
** Different mutations were detected at presentation and relapse
4.7.2.2  Patients with a FLT3 mutation at presentation
Twenty patients were studied who had a FLT3 mutation at presentation, 18 were 
ITD+  with  median  mutant  level  28%  (range  5%  -  91%)  and  2  had  D835Y 
mutations at about the 50% mutant level (Table 4.2). The median time to relapse 
for these 20 patients with a FLT3 mutation at presentation was 218 days (range 
38-716), which was significantly less than in those patients who had not had a
76FLT3 mutation at presentation (P = 0.008, Student's t-test). Five patients (25%) 
lost  their  FLT3  mutation  at  relapse.  All  had  presented  with  an  ITD  and  the 
mutant levels were 6%,  11%, 20%, 28% and 44% respectively. Polymorphism 
analysis demonstrated that the paired samples were from the same individual in 
4 cases from whom DNA samples were available. Representative gels from two 
patients  are  shown  in  Figure  4.2.  Only  RNA  was  available  in  the  remaining 
patient. The loss was confirmed by radioactive PCR. In 4 of the 5 patients, the 
percentage  of blast  cells  was  similar  in  the  presentation  and  relapse  samples 
(#25-28,  Table  4.2)  and  therefore  it  is  unlikely  that  the  mutation  had  been 
missed at relapse. In the remaining patient (#29), the blast cell count was lower 
at  relapse  (44%)  than  at  presentation  (95%).  However,  at  diagnosis  all  cells 
appeared to be heterozygous for the mutation (mutant level 44%), and therefore, 
even with the lower blast cell count, a heterozygous mutation would still have 
been well within the limits of detection of the technique.
Marker  KB9 D21S65 D21S270
Status  P
pt 1
Pt 2
Figure 4.2 Polymorphic marker analysis in 2 AML patients at 
presentation (P) and relapse (R). Both patients presented with 
a FLT3/ITD which was lost at relapse
Fifteen patients had a FLT3 mutation at both presentation and relapse. Two had 
D835Y mutations at both stages of their disease and  13  had ITDs.  Sequencing 
and semi-quantitative PCR showed that 6 patients relapsed with the same ITD at 
approximately  the  same  level  (#32-37,  Table  4.2).  The  median  difference 
between presentation and relapse in the level of mutant was 0% (range -3% to 
+3%).  Three of these patients had levels of mutant which were consistent with
77homozygosity  or  hemizygosity  in  most  blast  cells  at  both  presentation  and 
relapse  (#35-37).  Six patients relapsed with the  same  ITD but at an increased 
level, where the median difference between presentation and relapse in the level 
of mutant was 29.5% (range  13.5% to 45%) (# 38-43, Table 4.2).  In 1   of these 
patients,  3  different ITDs were detected at diagnosis  (mutant levels 28%,  3%, 
1%  respectively),  but  only  the  predominant  mutation  was  present  at  relapse 
(#42,  Table  4.2).  Another  patient  (#41,  Table  4.2)  had  2  different  ITDs  at 
diagnosis, mutant levels 26% and 2%, and both were increased at relapse, 56% 
and  14%  respectively.  The  remaining  patient  who  was  ITD+  at  presentation, 
mutant level 44%, relapsed with a different ITD, mutant level 60% (#44, Table
4.2). The relapse mutation was not detectable in the presentation sample using 
radioactive  PCR  analysis.  At  presentation  the  ITD  was  33bps,  nucleotides 
36503 - 36535 from the DNA sequence (Genbank accession number 13628652) 
whereas at relapse the ITD was 60 bps, 51  bps from nucleotides 36481  - 36531 
plus  an  additional  insertion  of  9  bps  (Figure  4.3).  Polymorphic  markers 
confirmed that the samples were from the same individual.
PRESENTATION
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Figure 4.3  Diagram to show the position of the different 
FLT3/ITDs detected in one patient at presentation and relapse
4.7.2.3 Survival analysis
Twenty  patients  who  remained  wild  type  FLT3  at  both  time  points  were 
compared  with  15  patients  who  presented  and  relapsed  with  the  same
78FLT3/ITD.  The  OS  in  the  latter  group  was  worse  and  this  was  statistically 
significant (p=0.01) (Figure 4.4). The majority of patients with a FLT3 mutation 
at  presentation  and  relapse,  relapsed  and  died  within  the  first  400  days  from 
diagnosis. Patients who changed the pattern of the mutation at relapse were not 
included  in  this  analysis  as  the  numbers  were  too  small  for  any  meaningful 
interpretations.
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Figure 4.4 Kaplan Meier curve demonstrating OS according to FLT3 
status at presentation and relapse (WTAVT: WT FLT3 at 
presentation and at relapse; MUT/MUT: FLT3/ITD at presentation 
and at relapse)
4.8 Discussion
It  is  now  more  than  a  decade  since  techniques  capable  of detecting  residual 
leukaemia at levels below the threshold of light microscopy have been used to 
improve clinical outcome. For example, the detection of MRD in children with 
ALL  during  induction  chemotherapy  has  been  shown  to  be  of  significant 
prognostic value, thus permitting the stratification of children with ALL to less 
toxic  or  more  intensive  arms  of  chemotherapy  (Van  Dongen  et  al,  1998). 
Similarly,  in  patients  with  CML  who  undergo  an  allogeneic  transplant,  DLI 
before the onset of haematologic relapse has been shown to be associated with 
an  increased  likelihood  of anti-leukaemic  response  and  a  return  to  complete 
cytogenetic and molecular remission.(van Rhee F,  1994) In acute promyelocytic 
leukaemia, conversion to PCR positivity for PML/RARa in 2  successive bone
79marrow samples post-consolidation chemotherapy is being used as a trigger to 
initiate salvage treatment. (Diverio et al,  1998) However, the clinical potential 
for such analysis in AML is restricted by the paucity of suitable markers. The 
recent  identification  of activating  mutations  in  the  FLT3  gene  as  the  most 
common mutation in AML, occurring in up to one third of adult patients, (Kiyoi 
et  al,  1999;  Yamamoto  et  al,  2001)  suggested  that  the  mutations  may  be  a 
relevant  marker  for MRD.  Results  presented  in this  chapter,  which  aimed to 
investigate  whether  FLT3  mutations  can  be  used  as  markers  of MRD,  first 
confirmed  that  the  mutation  is  only  found  in  leukaemic  cells.  Analysis  of a 
small group of 13 patients in morphological remission demonstrated that neither 
the presentation ITDs nor D835 mutation could be detected in bone marrow or 
peripheral blood  samples obtained after induction chemotherapy.  Eight of the 
patients had had mutant levels of 40% - 46% of total FLT3, indicating that the 
majority of cells carried the mutation (assuming heterozygosity),  and 2  of the 
patients  had  had  evidence  for  biallelic  mutations  or  loss  of one  allele,  with 
mutant levels of 74% and 90% respectively.
For a leukaemic marker to be clinically useful as an early predictor of relapse, it 
is important that the marker consistently reappears at relapse. However, 5 of the 
20 patients (25%) who were positive for a FLT3 mutation at diagnosis lost their 
mutation at relapse. All had had ITDs and the level of mutant suggests that in 3 
of them  at least half of the cells in the sample  analyzed carried the mutation. 
The  inability of the mutation to be detected at relapse  cannot be  attributed to 
insensitivity of the technique used, as in all 5 cases the negative results from the 
cold PCR used bone marrow samples and were confirmed by the more sensitive 
radioactive PCR, which can detect ITDs at least at the 0.5% level (see chapter 
3). Furthermore, in 4 of the 5 patients the blast cell counts were similar to those 
at presentation.
The  results  presented  in  this  chapter  are  consistent  with  2  studies,  one  by 
Nakano et al (1999) and the other by Shih et al (2002), in which 1  out of 6 ITD+ 
(16%)  and  1   out  of  17  ITD+  (6%)  patients  at  presentation respectively  were 
FLT3/WT at relapse, but it is in contrast to Schnittger et al (2002) who reported 
that  25  patients  with  a  mutation  at  presentation  all  relapsed  with  the  same
80marker.  However,  more  recently  Schnittger  et  al  (2004)  have  updated  their 
previous study, assessing 97 paired samples at diagnosis and relapse, and found 
a gain of a FLT3/ITD  in 4/55  cases  (7.2%)  and  loss  of the  mutation in 4/42 
(9.5%). Fifty one patients were negative at both time points, and 38 cases were 
positive for a FLT3/ITD at both time points.
A number of other issues arise that are relevant for MRD detection, particularly 
for ITDs. Two patients had evidence of more than 1   mutation at diagnosis, and 
in  1   of these  patients  only  1   of the  3  ITDs  was  detected  at  relapse.  This 
indicated that the different mutants were present in separate subclones, only 1  of 
which  survived or was  selected after chemotherapy.  In the  other patient both 
mutants were detected at relapse at increased levels, though in different relative 
proportions,  and  it  is  not possible to  determine  whether the  mutants  were  in 
separate clones which both survived, or whether the minor mutant was acquired 
on the  other allele  in a cell  which was  already heterozygous  for an  ITD  and 
neither clone was completely eliminated by the treatment. In addition,  1  patient 
with an ITD at diagnosis relapsed with a completely different ITD, which would 
present  as  a  false  negative  result  if mutation  sequence-specific  primers  were 
utilized  to  improve  the  sensitivity of the  assays  used.  In  fact,  Stirewalt  et al 
(2001)  reported nested quantitative real time PCR assays  for 4 AML  samples 
with  FLT3  ITDs  using patient-specific primers,  where  they  detected between 
0.01  and 0.001% of FLT3/ITD positive sample in a background of WT DNA. 
However,  these  assays  are  laboratory  intensive  requiring  the  development  of 
patient-specific primers and are only appropriate in cases where patients present 
and relapse with AML cells containing the same FLT3/ITDs. Analysis of FLT3 
mutations as an early indicator of relapse should therefore be used with caution.
The  results  presented  in  this  chapter  also  shed  light  on  the  role  of FLT3 
mutations in the pathogenesis of AML. The findings show that these mutations 
may be present in only a minority of blast cells at presentation, and at relapse 
the  ratio  of mutant to  WT  allele  frequently  increases,  as  seen  in  6  out  of 12 
patients with the same ITD mutation at presentation and relapse (#38-43, Table
4.2). Results in 3 of these patients were consistent with a greater proportion of 
ITD+ blast cells at relapse (#39-41), and in 1   patient (#39) relapse appeared to
81be  associated with the  development of homozygosity or hemizygosity for the 
mutant in at least some of the cells. This is in accordance with the recent study 
published by Schnittger et al (2004), where 24.5% of cases sustained the same 
level of mutant to WT type allele, but the majority of cases (63%) showed an 
increased  level.  This  indicates  that  the  FLT3  alterations  can  be  secondary 
mutations arising in an already malignant clone, with selection of the subclone 
containing the  FLT3  mutation because of the  growth or survival  advantage it 
confers.  Five out of 24 patients (21%) who were WT at presentation acquired 
FLT3  mutations  for  the  first time  in  either  first  or  second  relapse,  which  is 
similar to the  frequency found at presentation (Chapter 3;  Kiyoi  et al,  1999). 
This is fully in accord with the fact that FLT3 mutations are secondary events. It 
also indicates that the FLT3 pathway is active in myeloid cells at the stage of 
differentiation equivalent to the clonogenic  leukaemic  cell,  as the presence of 
these random  mutations  occurring in an already transformed clone  lead to  its 
further  selection.  The  observation that  at  relapse  1   out  of 20  patients  had  a 
different mutation and 5 had lost the FLT3 mutation is also compatible with this 
model.  For  this  to  occur,  another  subclone  would  need  to  develop  from  a 
leukaemic cell that had been present at diagnosis but did not contain the FLT3 
mutation. To outgrow the mutant FLT3+ cells, this subclone must have acquired 
alternative mutation(s) imparting a greater survival/growth advantage than that 
provided  by  the  original  FLT3  mutation.  One  possibility  is  a  secondary 
mutation in N-Ras as such mutations have been documented to arise in relapse 
when not present at diagnosis (Bartram et al,  1989; Nakano et al, 1999). In the 5 
patients  whom  we  studied  who  lost  FLT3  mutations  at  relapse,  only  one, 
however,  acquired  an  N-Ras  mutation.  (Ras  analysis  was  performed  in  Dr 
Bowen’s lab in Ninewells Hospital, Dundee). This is a potential target as FLT3 
activates N-Ras, (Dosil et al,  1993) and the rarity of FLT3 mutations and N-Ras 
mutations in the same blast cells suggests that both mutations are predominantly 
using the same pathways (Kiyoi et al,  1999). Consequently, in future it may be 
informative  to  screen  for mutations  in other candidate  genes.  These  data also 
demonstrate that patients who present and relapse with a FLT3/ITD have a very 
poor outcome compared to patients with wild type allele (Figure 4.4). However, 
this  finding  will  need  to  be  validated  further  in  studies  incorporating  a  large 
number of patients.
82In  summary  this  study  of paired  diagnosis/relapse  samples  indicates  that  the 
majority of patients with FLT3/ITD mutations relapse with an equal or higher 
level of the same mutation. A smaller but not insignificant number of patients 
lose the mutation at relapse or relapse with a new one. For this small group of 
patients  it  seems that the FLT3/ITD  is not present within the  leukaemic  stem 
cell that leads to disease relapse. It is also suggests that these mutations are late 
hits during the process of leukaemogenesis and might have implications for the 
therapeutic use of FLT3 kinase inhibitors in patients whose cells express FLT3 
mutations.  (Zhao  et  al,  2000;  Tse  et  al,  2001,  Levis  et  al,  2001)  As  these 
mutations  are  secondary  events,  there  will  always  be  a  high  probability  that 
leukaemic subclones not containing the mutant will be present which will have a 
selection advantage in the presence of a FLT3 kinase inhibitor. These findings 
have important clinical implications for studies evaluating the efficacy of FLT3 
inhibitors  in  patients  with  AML  and  should  be  considered  when  clinical 
resistance to these compounds occurs.
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5.1  Introduction
Conventional cancer chemotherapy relies on the premise that anti-cancer drugs 
will preferentially kill rapidly dividing tumour cells rather than normal cells. In 
order to eradicate tumour cells and maintain a complete remission status, large 
doses of drugs are typically used. However, this may cause profound toxicity, 
increasing the rate of mortality and morbidity. One of the most important goals 
therefore  of  modem  anti-cancer  research  is  to  develop  drugs  with  better 
discrimination  between  malignant  cells  and  normal  cells.  In  recent  years, 
tremendous  efforts have  been focused on the  development of kinase targeted 
therapies, as aberrant protein kinases are thought to be critical molecules for the 
development  of human  cancer.  In  this  field,  the  most  successful  examples 
include  the  small  molecule  kinase  inhibitor  STI571  (Imatinib/Gleevec, 
Novartis)  for  the  treatment  of chronic  myeloid  leukaemia  (CML),  and  the 
monoclonal antibody Trastuzumab (Herceptin) directed against the RTK HER2 
for the treatment of breast cancer.
CML is a clonal stem cell disorder in which the reciprocal translocation t(9;22) 
generates  two  novel  fusion  genes:  BCR-ABL  on  the  derivative  22q- 
chromosome  and  ABL-BCR  on  chromosome  9q+.  The  fusion  protein  BCR- 
ABL  has  constitutive  kinase  activity  that  deregulates  signal  transduction 
pathways. Imatinib occupies the ATP-binding site of the molecule and prevents 
phosphorylation of downstream  substrates  that  are  involved  in regulating the 
cell  cycle.  This  results  in  inhibition  of  cell  proliferation  and  induction  of 
apoptosis  in  BCR-ABL  positive  cells.  In  colony-forming  assays  that  used 
mononuclear cells  from  peripheral  blood or bone  marrow from patients  with 
CML,  imatinib  produced  a  92%-98%  reduction  in the  number  of BCR-ABL 
positive  colonies  (Druker  et  al,  1996).  Imatinib  has  synergistic  or  additive 
activity  with  interferon-alpha,  hydroxyurea,  daunorubicin,  doxorubicin, 
etoposide,  cytarabine,  cyclophosphamide,  and  vincristine  against  BCR-ABL 
positive  cells  (Fang  et al,  2000;  Thiesing  et al,  2000;  Kano  et al,  2001).  In
84recent  years,  the  introduction  of  imatinib  has  completely  changed  the 
therapeutic  algorithm  in the  management  of CML,  and  several  studies  have 
shown  its  efficacy  in patients  either in the  chronic  phase  or blastic  crisis  of 
CML. In a retrospective study comparing the progression free survival (PFS) of 
143  patients  who  received  imatinib  after  failure  of interferon-based  therapy 
with 264 historical controls managed with conventional therapy (as per MRC 
CML3  trial),  a  significant benefit was  demonstrated  for patients  treated with 
imatinib  (p=0.0065).  However,  an  overall  survival  benefit  was  confined  to 
those patients who achieved a cytogenetic response (Martin et al, 2003).  In a 
phase  III  randomised  study,  imatinib  and the  combination  of interferon plus 
cytarabine were compared, and imatinib was found to be superior with respect 
to complete haematologic response and major or complete cytogenetic response 
(O’Brien  et  al,  2003).  Since  a  large  fraction  of  patients  crossed  from 
interferon/cytarabine to imatinib, no difference in OS was observed. In addition 
to  its  superior  efficacy,  imatinib  offered  clear  quality  of  life  advantages 
compared  with  interferon  and  cytarabine,  including  in  those  patients  who 
crossed over during the study period (Hahn et al, 2003). In an effort to improve 
PFS and OS, several investigators are currently exploring the use of imatinib in 
combination with other drugs such as interferon and cytarabine.
However,  the  development  of resistance  to  this  drug  is  a  frequent  setback, 
particularly  in  patients  in  advanced  phases  of  the  disease  (Reviewed  by 
Deininger et al, 2005). Several mechanisms of resistance have been described, 
the most frequent are amplification and/or mutations of the BCR-ABL gene. To 
overcome resistance, several approaches have been studied in vitro and in vivo. 
They  include  dose  escalation  of  imatinib,  combination  of  imatinib  with 
chemotherapeutic drugs, alternative BCR-ABL inhibitors, inhibitors of kinases 
downstream  of BCR-ABL,  famesyl and geranylgeranyl  transferase inhibitors, 
histone deacetylase, proteasome and cyclin-dependent kinase inhibitors, arsenic 
trioxide, hypomethylating agents, troxacitabine, targeting BCR-ABL messenger 
RNA, and immunomodulatory strategies (Deininger et al, 2005). It is important 
to  understand  that  these  approaches  differ  in  efficiency,  which  is  often 
dependent  on  the  mechanism  of  resistance.  Further  investigation  into  the 
molecular mechanisms of disease and how to specifically target the abnormal
85processes will guide the design of new treatment modalities in future clinical 
trials.
In  addition  to  small  molecule  inhibitors,  monoclonal  antibodies  have  been 
developed  that  target  cell  surface  receptor  molecules.  The  humanised 
monoclonal anti-HER2 antibody Trastuzumab was the first genomic-research- 
based  targeted  anti-cancer  therapeutic  to  be  approved  by  the  FDA  for  the 
treatment of breast cancer (Shepard et al, 1991). HER2 is a member of the EGF 
receptor family and was first identified as a transforming gene in chemically- 
induced  rat  neuroblastomas.  The  HER2/NEU  gene  is  amplified  in 
approximately 30% of patients with breast cancer and is  a prognostic marker 
for adverse outcome (Slamon et al,  1987; Carter et al,  1992).  Several clinical 
studies  have  demonstrated  objective  response  rates  in previously treated  and 
untreated patients with metastatic breast cancer (Tan et al, 2003). For example, 
in a randomised study of 469 patients by Salmon et al (2001) in women with 
metastatic breast cancer overexpressing HER2, the addition of trastuzumab to 
chemotherapy was associated with a longer time to disease progression (median
7.4  vs. 4.6 months; p<0.001), a longer duration of response (median 9.1 vs. 6.1 
months; p<0.001), a lower rate of death at 1   year (22% vs. 33%, p=0.008), and 
longer survival (median survival 25.1 vs. 20.3 months; p=0.046).
Herceptin and imatinib are powerful examples of the potential clinical utility of 
kinase  targeted  therapy  and  therefore  broad  application  of  this  treatment 
strategy to  other cancers  is  expected over the next  few years.  Since  FLT3  is 
expressed  on the  surface  of blast  cells  in the  majority  of AML  patients  and 
approximately  one  quarter  of  these  patients  carry  an  activating  mutation 
conferring  a  worse  prognosis,  targeting  FLT3  using  specific  inhibitors  may 
establish  new  treatment  options  for  the  treatment  of AML.  Indeed,  several 
tyrosine  kinase  inhibitors which were  not originally developed with FLT3  as 
the intended target have been reported to inhibit FLT3 in cell lines and primary 
leukaemic blasts.  At the time the work outlined in this chapter was started, a 
number  of inhibitors  had  become  available,  and  a  dozen  studies  have  since 
demonstrated their in vitro and in vivo efficacy in cell lines, primary blast cells 
and  animal  models  (Table  5.1).  Four  inhibitors  were  used  in  the  studies
86reported here. AG1295 (6,7-Dimethyl-2-phenylquinoxaline) and AG 1296 (6,7- 
Dimethoxy-2-phenylquinoxaline) are compounds of the tyrphostin class which 
potently inhibit both PDGF and SCF receptor activation in intact cells with a 
high degree of specificity (Gazit et al, 1996; Kovalenko et al, 1994; Banai et al, 
1998; Ueda et al, 2002). Tyrphostins are not very soluble and are not amenable 
to  use  in  patients.  CEP-701,  an  indolocarbazole  derivative,  is  a  relatively 
selective FLT3 inhibitor with an IC50 of 3 nM in in vitro kinase and cell-based 
FLT3  autophosphorylation  assays  (Levis  et  al,  2002).  The  staurosporin 
derivative  PKC-412  was  originally  identified  as  a protein kinase  C  inhibitor 
(Meyer et al, 1989) and subsequently shown to inhibit members of the class III 
RTKs, including vascular endothelial growth factor receptor (VEGFR), platelet 
derived  growth  factor  receptor  (PDGFR),  KIT  and  FLT3  (Weisberg  et  al, 
2002).  PKC-412  was  identified  as  a  FLT3  inhibitor  based  on  its  selective 
inhibition of Ba/F3 cells transfected with FLT3/ITD. The IC50 for inhibition of 
proliferation and phosphorylation was  in the order of lOnM  (Weisberg et al, 
2002).
5.2  Material and methods
5.2.1  Samples from AML patients
Patient samples were obtained from peripheral blood or bone marrow of adults 
with newly diagnosed or relapsed AML. For fresh samples, mononuclear cells 
were recovered by Ficoll-Hypaque density centrifugation, washed thoroughly, 
suspended in growth medium [RPMI 1640 tissue culture medium (Gibco BRL, 
Paisley,  UK)  supplemented  with  10%  fetal  calf  serum  (FCS)  and  5% 
amoxicillin]  and incubated in a humidified  5%  CO2  atmosphere  at  37°C. No 
cytokines  were  added.  For frozen samples,  bone  marrow or peripheral  blood 
mononuclear  cells  were  thawed  slowly  and  cultured  in  Iscove’s  solution 
(Gibco, UK) supplemented with  10% FCS, 5% amoxicillin, for 4 hours in 5% 
CO2 at 37°C. Subsequently, viability was assessed by trypan blue dye exclusion 
assay which relies on an alteration in membrane integrity, as determined by the
87uptake of dye by dead cells, thereby giving a direct measure of cell viability. 
Only samples with greater than 80% viability were used.
Table 5.1 Summary of FLT3 inhibitors
INHIBITOR 
Herbimycin  A
OTHER RTK 
TARGETS 
PDGFR, EGFR
CELLS TESTED
FLT3/ITD cDNA transfected 32D & Cos7 
cells
RESULTS
Inhibition of proliferation
REF
Zhao et al, 
2000
AG 1295 PDGFR, KIT
Mice transplanted with transfected 
32D/ITD cells
Primary blasts from patients with AML 
(n=23)
Prolonged latency of disease or prevented 
leukaemia
Cytotoxic to FLT3/ITD cells Levis et al, 
2001
AG 1296 PDGFR, KIT Chimeric TEL/FLT3 transfected Ba/F3 
cells
Inhibition of phosphorylation (IC5 o 0.3 
pM)
Inhibition of proliferation (IC50 1.5 pM) 
Increase in apoptosis
Tse et al, 
2001
FLT3/ITD transfected Ba/F3 cells Inhibition of auto phosphorylation (IC50 
lpM)
Inhibition of proliferation  (IC50 0.5-0.8 
pM)
Tse et al, 
2002
Primary blasts from patients with AML Inhibition of proliferation of FLT3/ITD 
blasts
CEP-701 PDGFR, KIT, 
FMS,
FLT3/ITD cDNA transfected Ba/F3 cells 
(BaF3/ITD)
Primary blasts from patients with AML 
(n=8)
Balb/c mice injected with BaF3/ITD cells
Inhibition of phosphorylation ( IC50 2nM) 
Inhibition of proliferation of BaF3/ITD 
cells (IC50 5nM)
Induced cytotoxicity in 3/4 with 
FLT3/ITD
Prolonged survival of mice
Levis et al, 
2002
SU5416 PDGFR, KIT, 
FMS, VEGFR
FLT3/ITD cDNA transfected Ba/F3 cells Inhibition of proliferation  (IC50 250nM ) 
Inhibition of phosphorylation (IC50 
lOOnM)
Yee et al, 
2002
SU11248 PDGFR, KIT, 
FMS,
RS411 cell line 
(WT FLT3 cell line)
MV411  cell line (FLT3/ITD cell line)
Inhibition of phosphorylation of STAT5 
and MAP kinase
Induction of apoptosis
PKC-412 Protein kinase 
C, VEGFR, 
PDGFR, KIT
BaF3/ITD cells 
BaF3/D835 cells
BaF3/ITD cells
Balb/c mice injected with BaF3/ITD cells
Inhibition of proliferation (IC50 lOnM ) 
Inhibition of proliferation (IC50 < lOnM )
Induction of apoptosis 
Inhibition of phosphorylation
Prevention of leukaemia
Weisberg 
et al, 2002
RTK: receptor tyrosine kinase; PDGFR: platelet-derived growth factor receptor; EGFR: epidermal 
growth factor receptor; VEGFR: vascular endothelial growth factor receptor5.2.2  Mutational analysis
Mutational analysis of FLT3 was performed on all AML samples as described 
in chapters 3.4.1 and 4.6.2.2
5.2.3 Inhibitors
PKC-412  was  obtained  from  Novartis  Pharma  AG,  Basel  Switzerland,  the 
indolocarbazole CEP-701  from Cephalon Incorporation, USA, and tyrphostins 
AG1295  and AG1296  from  LC  Laboratories,  Woburn,  MA,  USA.  All  these 
compounds were dissolved in dimethyl sulfoxide (DMSO) to create 4mM stock 
solutions which were frozen at -20°C in glass (CEP-701, PKC-412) or plastic 
vials  (tyrphostins)  and  diluted  appropriately  before  each  experiment.  Final 
concentration of DMSO in growth medium did not exceed 0.1 %.
5.2.4 Cell culture and MTS assay
Mononuclear cells from patients were plated in triplicate at 2xl04 cells/lOOpl 
per well in 96-well plates with growth medium and in the presence of varying 
concentrations of inhibitors. Inhibitor-free controls contained the same amount 
of DMSO as in the experimental groups. Cells were incubated in a humidified 
5% CO2 atmosphere at 37°C for 48 (thawed cells) or 72 hours (fresh cells). Cell 
viability was measured using the CellTiter96  non-radioactive cell proliferation 
assay  (Promega,  Madison,  WI,  USA)  according  to  the  manufacturers’ 
instructions. This is a colorimetric method for determining the number of viable 
cells which uses a novel tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5- 
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt, MTS) 
and  an  electron  coupling  reagent  (phenazine  methosulfate,  PMS).  MTS  is 
bioreduced  by  viable  cells  into  a  formazan  product  that  is  soluble  in  tissue 
culture  medium.  The  conversion  of MTS  into  aqueous,  soluble  formazan  is 
accomplished by dehydrogenase enzymes  found in metabolically active  cells. 
The quantity of formazan product, as measured by the absorbance at 562 nm, is 
directly  proportional  to  the  number  of  living  cells  in  the  sample.  At  the
89indicated time point (48 hours for thawed cells or 72 hours for the fresh cells), 
20pi of the combined MTS/PMS solution was added to each well and the plates 
incubated  for  a  further  4  hours.  The  plates  were  then  read  in  an  ELISA 
microplate  reader  at  562  nm.  The  absorbances  were  corrected  for  blank 
readings obtained from culture medium without cells.
5.2.5  Statistical analysis
The  Student’s  t-test  was  utilised in  order to  compare  results  obtained  in the 
MTS assays.
5.3  Results
5.3.1  Proliferation assays using tryphostins AG1295 and AG  1296
Twelve fresh samples from patients with de novo AML were studied using the 
tyrphostins AG1295 and AG1296.  Three were female and 9 male. The median 
age at presentation was 41 years (range 15-60). Patient characteristics including 
the  cytogenetic  risk  group  are  provided  in  Table  5.2.  Nine  patients  were 
FLT3/ITD  negative  and  3  FLT3/ITD  positive.  None  of  them  harboured  a 
FLT3/TKD  mutation.  AG1295  and  AG1296  were  used  at  the  following 
concentrations:  0.5,  1,  2,  3,  4,  5,  7.5  and  10  pM  according  to  previous 
published data (Levis et al, 2001). Figures 5.1  and 5.2 show the dose response 
curves  obtained.  The  data were grouped according to FLT3/ITD  status  and a 
mean response for each AG1295 and AG 1296 concentration was calculated and 
expressed as a percentage of the mean optical density (OD) of the control wells. 
Errors  bars  represent  the  standard  deviation  (SD)  of the  mean  OD  of the 
treatment  points.  The  sensitivity  towards  the  tyrphostin  AG 1295  differed 
between cells harbouring the wild type and mutant receptor (Figure 5.1). The 
cytotoxicity was more apparent in blast cells with the mutation, however, when 
the t-test was  used to  compare the  mean cytotoxicity between wild type  and 
mutant blasts  at each concentration of the inhibitor, there was no  statistically
90significant difference. There was a slight cytotoxic effect with AG1296, but this 
was not significantly different from the control (Figure 5.2).
Table 5.2 Patient demographics and FLT3 status
Patient Age Sex Cytogenetic risk 
group
FLT3
1 39 M Standard WT
2 29 M Standard WT
3 57 M Favourable WT
4 55 M Standard WT
5 42 F Standard WT
6 56 M Favourable WT
7 60 M Favourable WT
8 41 M Poor WT
9 54 F Standard WT
10 40 M Standard ITD
11 41 M Standard ITD
12 15 F Poor ITD
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Figure 5.1 Dose response curves of FLT3/ITD and non-ITD AML samples treated with AG1295
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Figure 5.2 Dose response curves of FLT3/ITD and non-ITD AML samples treated with AG1296
5.3.2  Proliferation assays using AG1295,  CEP-701 and PKC-412 combined 
with cytarabine
In order to determine whether the addition of standard cytotoxic agents might 
potentiate the effects of tyrosine kinase inhibitors on primary AML blast cells, 
proliferation assays were performed using a fixed dose of  AG1295, CEP-701
92or PKC-412 incubated with varying doses of cytarabine. The two agents were 
added  simultaneously to  the  cells  and  cytarabine  was  used  at three  different 
concentrations: 0.001, 0.01 and O.lmg/ml. Cells were incubated in a humidified 
5% CO2 atmosphere at 37°C for 48 hours and the MTS assay was performed as 
described  in  Material  and  Methods  (5.2.4).  Thawed  blast  cells  were  chosen 
from three patients with FLT3  mutations  (2  FLT3/ITD,  1   FLT3/TKD)  and 3 
patients with WT FLT3 protein. The patients’ characteristics are given in Table 
5.3.
Table 5.3 Patient demographics and FLT3 status
Patient Age Sex Cytogenetic risk group FLT3 Status
1 41 M Poor WT
2 56 M Favourable WT
3 39 M Standard WT
4 41 M Standard ITD
5 45 M Standard TKD
6 40 M Standard ITD
TKD: tyrosine kinase domain mutation
Figure 5.3 shows the dose response of each sample treated with either AG1295, 
CEP-701,  PKC-412,  or  cytarabine  at  a  concentration  of  O.lmg/ml.  In 
accordance with the results reported above using AG 1295 in fresh primary blast 
cells, a similar effect was observed in thawed blast cells. The cytotoxic effect of 
the inhibitor was more apparent in blast cells harbouring a FLT3 mutation than 
in  those  with  WT  FLT3  (Figure  5.3).  AG1295  at  a  concentration  of 2pM 
produced a strong cytotoxic effect in blast cells from 2 of the 3 patients with a 
mutation  compared  to  little/no  effect  in  cells  from  the  3  patients  with  WT 
FLT3.  However, this difference was not statistically significant. AG1295  at a 
concentration of 5pM produced statistically significant cytotoxicity (p=0.02) in 
mutant  compared  to  WT  samples  (Figure  5.3).  CEP-701  was  also  more 
cytotoxic  to  blast  cells  harbouring  a  FLT3  mutation  (Figure  5.3),  and  this
93difference  was  statistically significant (p=0.02) at 20nM  CEP-701, but not at 
5nM (p=0.1). Of note, 20nM CEP-701 was also slightly cytotoxic to blast cells 
with WT FLT3 (median cytotoxicity 27%), and the difference in the cytotoxic 
effect  at  5  and  20nM  CEP-701  in  these  cells  was  statistically  significant 
(p=0.03).  PKC-412  was  also  cytotoxic  to  blast  cells  with  FLT3  mutations, 
however,  there  was  some  effect  in  blast  cells  without  FLT3  mutations.  For 
example, in Patient 2 (WT FLT3), PKC-412 at 5 and 20nM produced 47% and 
42% cytotoxicity, respectively. Even though there was a trend for PKC-412 to 
be  more  toxic  to  cells  harbouring  FLT3  mutations,  this  effect  was  not 
statistically significant at either concentrations (5 or 20nM). Paradoxically, the 
maximum  cytotoxic  effect  with  PKC-412  was  achieved  at  the  minimum 
concentration (5nM rather 20 nM) (Figure 5.3).
When  cytarabine  was  added  with  the  inhibitors,  different  patterns  of 
cytotoxicity were observed for each patient sample. In samples from patient  1  
(WT  FLT3),  cytarabine  produced  a  35%  cytotoxic  effect  at  the  maximum 
concentration of O.lmg/ml, but this was not augmented by adding AG 1295 or 
PKC-412 (Figure 5.4 A, C). However, when CEP-701  was added the cytotoxic 
effect  of  cytarabine  was  slightly  enhanced,  with  55%  killing  at  O.lmg/ml 
cytarabine and 20nM CEP-701 (Figure 5.4 B). In patient 2 (WT FLT3), neither 
cytarabine,  AG 1295,  CEP-701  nor  the  two  combined  produced  any  major 
effect (Figure 5.5A, B). However, PKC-412 produced 40% cytotoxicity on its 
own  which  was  not  augmented  by  cytarabine  (Figure  5.5C).  Samples  from 
patient 3  (WT FLT3)  showed only 20% cytotoxicity with cytarabine alone at 
the maximum concentration of O.lmg/ml, although this was augmented when 
combined  with  AG1295  or  CEP-701  (Figure  5.6A,  B).  PKC-412  had  little 
cytotoxic effect when used alone, and this was not enhanced by the addition of 
cytarabine (Figure  5.6C).  In patient 4 (FLT3/ITD), cytarabine alone produced 
nearly  40%  cytotoxicity  at  0.01 mg/ml  concentration.  Even  though  all  three 
inhibitors showed considerable cytotoxic effect when used alone, combination 
with cytarabine did not enhance the cytotoxicity (Figure 5.7A, B, C). In patient 
5  (FLT3/D835),  cytarabine  produced  a  major  cytotoxic  response,  with  80% 
cytotoxicity at O.lmg/ml. Similarly, as single agents all three inhibitors showed 
considerable cytotoxicity, and there was therefore, little or no additional effect
94when they  were  combined with cytarabine  (Figure  5.8A,  B,  C).  In patient  6 
(FLT3/ITD), cytarabine at the minimum concentration of 0.001 mg/ml produced 
a 55% cytotoxic effect which remained unchanged at 0.01  and O.lmg/ml. All 
three inhibitors produced a major cytotoxic effect, which was not enhanced by 
cytarabine (Figure 5.9A, B, C).
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Figure 5.3 Cytotoxic effect of AG1295, CEP-701, PKC-412 and cytarabine 
(Ara-C) in blast cells from patients with and without FLT3 mutations
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Figure 5.4  Dose response curves of cells from an AML patient with FLT3 WT treated with Cytarabine (Ara-C)
alone and in combination with AG1295, CEP-701 or PKC-412
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Figure 5.5  Dose response curves of cells from an AML patient with FLT3 WT treated with Cytarabine (Ara-C)
alone and in combination with AG1295, CEP-701 or PKC-412
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Figure 5.6  Dose response curves of ceils from an AML patient with FLT3 WT treated with Cytarabine (Ara-C)
alone and in combination with AG1295, CEP-701 or PKC-412
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Figure 5.7  Dose response curves of cells from an AML patient with FLT3/ITD treated with Cytarabine (Ara-C)
alone and in combination with AG1295, CEP-701 or PKC-412
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Figure 5.8  Dose response curves of cells from an AML patient with FLT3/TKD treated with Cytarabine (Ara-C)
alone and in combination with AG1295, CEP-701 or PKC-412Patient 6
B
Ara-C 100
Ara-C+2 pM  AG1295
Ara-C+5 pM AG1295
© o o 0
Ara-C 100
Ara-C+ 5nM CEP-701
80 Ara-C+ 20nM CEP-701
60
40
20
0
© o 0 ©
100 Ara-C
Ara-C+ 5nM PKC-412
80
Ara-C+ 20nM PKC-412
60
40
20
0
o o
Cytarabine (mg/ml)
Cytarabine (mg/ml) Cytarabine (mg/ml)
Figure 5.9  Dose response curves of cells from an AML patient with FLT3/ITD treated with Cytarabine (Ara-C)
alone and in combination with AG1295, CEP-701 or PKC-4125.4 Discussion
Identification of the key role of protein kinases as potential  oncoproteins has 
led to the  emergence  of a new era of targeted therapies.  The  introduction of 
imatinib,  an agent targeting the causative molecular event  in CML, has been 
heralded  as  a major advance  in the  treatment  of cancer.  Certainly,  the  early 
phase  I/II  and  more  recent  clinical  trials  with  imatinib  have  validated  the 
concept that a precise understanding of the pathogenesis of a cancer can lead to 
more effective and less toxic therapies.
The high  incidence of activating mutations  of FLT3  (see chapter 3) in AML 
suggested  that  inhibitors  of mutant  FLT3  might  have  potential  therapeutic 
activity in these patients. The preliminary data in this chapter showed that the 
inhibitors  AG 1295,  CEP-701  and  PKC-412  could  induce  a  greater  in  vitro 
cytotoxic  effect in blast cells of patients  with FLT3/ITDs  when compared to 
cells  with the  WT of the receptor.  This effect was  apparent in samples  from 
patients with FLT3/ITDs, and was also observed in a patient with a FLT3/TKD 
mutation (Patient 5, Figure 5.8). Even though this later observation relied on a 
sample from a single patient, these agents may also have a role in patients with 
FLT3/TKD  mutations.  However,  large  studies  will  be  required  in  order  to 
assess potential applicability. The cytotoxicity was dose dependent for AG 1295 
and CEP-701, but not for PKC-412, where the inhibitor at 5nM concentration 
was more potent compared to 20nM (Figure  5.3). At present there is no clear 
explanation for this observation.
These data are in agreement with other studies which have explored potential 
cytotoxicity of FLT3 inhibitors in primary AML blasts. In a study by Levis et 
al  (2001)  using  AG 1295  on  primary  blasts  from  23  patients  with  AML, 
cytotoxic responses were observed in 8 FLT3/ITD compared to  15  FLT3/WT 
specimens  (p=0.001).  The  difference  was  statistically  significant  at  each 
concentration point (0.5,  1, 2, 3, 4 and 5  pM).  In another study by the same 
group  using  CEP-701  on  primary  AML  samples  from  8  patients,  3  of  4 
FLT3/ITD samples displayed a cytotoxic response to CEP-701, as did a single
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the D835 mutant sample and the other 2 WT samples, did not respond to CEP- 
701. A cytotoxic effect could be seen at approximately 5 nM and was maximal 
at 50nM (Levis et al, 2002). PKC-412 has been found to be cytotoxic to Ba/F3 
cells  transfected  with  FLT3/ITD  but  non-toxic  in  parental  Ba/F3  cells  at 
concentrations up to lOOnM (Weisberg et al, 2002). Furthermore, survival was 
significantly prolonged in PKC-412 treated Balb/c mice transplanted with cells 
transduced  with  a  FLT3/ITD  expressing  retrovirus.  The  majority  of animals 
treated  with  placebo  developed  characteristic  features  of  FLT3/ITD 
myeloproliferative  disorder,  whilst  none  of those  treated  with  PKC-412  did 
(Weisberg et al, 2002).
However,  if FLT3  mutations are  secondary events  (see  chapter 4), there will 
always  be  a  high  probability  that  leukaemic  subclones  not  containing  the 
mutant will be present which will have a selection advantage in the presence of 
a  FLT3  kinase  inhibitor.  Clinically,  this  may  result  in  relapse  with  a 
predominant FLT3 WT clone, suggesting that FLT3 inhibitors should probably 
be used  in combination with conventional  chemotherapy.  Experience in anti­
neoplastic  treatment  has  shown over the  years  that  monotherapy with  single 
agents  is  unlikely  to  be  curative,  and  the  development  of  resistance  to 
chemotherapeutic  drugs  is  a  ubiquitous  problem  in  the  treatment  of 
haematological  and  non-haematological  cancer.  This  applies  not  only  to 
conventional  cytotoxics  but also to  inhibitors,  as  it  is  becoming  increasingly 
apparent that resistance to tyrosine  kinase  inhibitors  is  an emerging problem 
with therapeutic implications. For example, as clinical experience with imatinib 
grows in CML, some patients become resistant, failing to achieve cytogenetic 
response.  Several mechanisms have been implicated  such as  amplification of 
BCR/ABL  or  mutations  in  the  BCR/ABL  protein  altering  imatinib  binding 
characteristics, or through indirect modulation of kinase function (Deininger et 
al, 2005).  Therefore in the future, treatment with conventional cytotoxics and 
inhibitors is more likely to be offered as combination rather than monotherapy.
As cytarabine remains the backbone of modem anti-leukaemic treatment, it was 
therefore used with inhibitors in combination experiments.  The results of this
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with conventional cytotoxic agents can provide some benefit. However, what it 
became  apparent  was  the  variability  in  the  cytotoxic  effect  from  patients’ 
sample  to  sample.  These  different  patterns  of  cytotoxicity  suggest  that 
treatment might have to be individualised using in vitro studies with patients’ 
samples  in  order  to  assess  potential  cytotoxicity  prior  to  introducing  the 
combination  into  clinical  practice.  However,  such  approach  would  be 
practically difficult to apply to each patient as it remains laborious and difficult 
to  standardise.  More  importantly,  patients  presenting  with  AML  require 
immediate  treatment without delay.  Furthermore,  the  interpretation would be 
difficult  as  in  vitro  models  do  not  necessarily  represent  in  vivo  behaviour 
(Smith  et  al,  2004).  Undoubtedly,  results  of in  vitro  experiments  should  be 
interpreted with caution when transferred to clinical practice.
Since the work presented in this chapter was completed,  several studies have 
been  published  looking  at  the  “combination  model”  using  conventional 
cytotoxic drugs with inhibitors.  SU11248 was found to  synergistically inhibit 
the proliferation of primary AML myeloblasts with a FLT3/ITD but not WT 
FLT3  when used with cytarabine (Yee et al, 2004).  CEP-701  also induced in 
vitro  cytotoxicity  in  a  synergistic  fashion  when  used  simultaneously  or 
immediately following exposure to chemotherapeutic agents, either cytarabine, 
daunorubicin, mitoxantrone or etoposide (Levis et al, 2004).  Interestingly, the 
sequence in which the chemotherapy and CEP-701 were administered appeared 
to be important because treatment of cells with CEP-701 prior to the addition of 
chemotherapy  seemed  to  antagonise  the  cytotoxic  effects  of agents  such  as 
cytarabine  and  etoposide.  This  may  be  because  inhibitors  block  cells  from 
cycling and therefore, cycle specific cytotoxic agents (i.e. cytarabine) lose their 
potency.
At  present,  phase  I  and  II  trials  using  these  inhibitors  as  monotherapy  in 
patients with AML have failed to show major clinical responses. For example, 
in  a phase  I/II  trial  using  CEP-701  as  salvage  treatment  in  14  patients  with 
refractory,  relapsed or poor risk AML expressing FLT3  activating mutations, 
minor  clinical  efficacy  was  observed.  In  5  out  of  14  patients,  CEP-701
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range  of  1%-10%  in  4  patients,  and  one  patient  showed  a  decrease  in  the 
percentage  of  bone  marrow  blasts  to  less  than  5%  (Smith  et  al,  2004). 
However, none of the responses were durable (2 weeks to 3 months). In another 
study by Stone et al (2004) using PKC-412 as monotherapy in 20 patients with 
relapsed/refractory AML,  the peripheral  blast  count decreased by  50%  in  14 
patients, but only 6 patients showed a 50% reduction in the blast count in the 
bone  marrow.  Of note,  2  patients  achieved  less  than  5%  blasts  in the  bone 
marrow.  Again,  none  of the patients  sustained a durable response.  In a third 
Phase II study by Giles et al (2003) of 55 patients with refractory AML/MDS, 
modest  clinical  activity  was  observed  using  SU5416.  This  was  restricted  to 
only  4  patients  (7%)  who  achieved  either  a  partial  or  haematological 
improvement, whilst, disappointingly, the overall median survival for the entire 
group  of  patients  with  AML  was  12  weeks.  This  study  also  raised  the 
possibility  of  unacceptable  toxicity  when  inhibitors  were  combined  with 
conventional  chemotherapy.  For  example,  7%  of  patients  developed 
thromboembolic  events  while  on  SU5416  as  monotherapy.  However 
thromboembolic  events  in the  range  of 42%  have  been  reported  for patients 
with solid tumours treated with SU5416 plus gemcitabine (Kuenen et al, 2002) 
and  cisplatin,  and  22%  when  combined  with  5-fluorouracil  and  leucovorin 
(Rosen et al, 2000).
In conclusion, the growing evidence for an important role of FLT3 mutations in 
AML suggests a potential for the use of FLT3 inhibitors in the treatment of this 
disease. However, as in at least some patients, FLT3 mutations are likely to be 
secondary  events  (chapter  4),  and  there  is  the  potential  of developing  drug 
resistance  to  FLT3  inhibitors,  it  is  more  likely  that  multi-agent  combination 
regimens will be used in the treatment of AML in the near future. The use of 
these drugs has already raised several questions which will need to be answered 
prior to  potential  incorporation into  clinical practice.  As  in vivo  and  in  vitro 
efficacy  has  been  shown  in  patients  with  AML  irrespective  of their  FLT3 
status,  should  the  use  of  inhibitors  be  restricted  to  patients  with  FLT3 
mutations, in patients over- expressing FLT3, or used in all patients with AML 
who enter these trials?  At which stage of the disease should these inhibitors be
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refractory disease)?  Should patients above the age of 60, where experimental 
treatments are needed more, be considered for this type of treatment as first line 
therapy?  Is  there  a role  for inhibitors targeting minimal  residual  disease?  As 
several  questions  remain  to  be  answered,  patients  offered  this  type  of 
therapeutic modality should only be treated as part of large clinical trials.
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Conclusions and future directions
The  tyrosine  kinase  receptor  FLT3  is  expressed  on  early  haemopoietic 
progenitors,  B-cell  precursors  and  macrophage  precursors.  FLT3  plays  an 
important role  in early haemopoietic progenitor proliferation and  survival,  as 
well  as  in  macrophage  and  dendritic  cell  differentiation.  In  AML,  FLT3  is 
highly  expressed  in  approximately  90%  of cases.  Nakao  et  al  (1996)  first 
identified  FLT3  mutations  in AML  in  1996  during  an  investigation  into  the 
incidence  and  distribution of FLT3  mRNA  in  samples  from  adult AML  and 
childhood ALL patients.  Unexpectedly long fragments were  detected in PCR 
products of the JM domain in 5 out of 30 (16%) AML patients. Further analysis 
showed that they all contained a tandemly duplicated sequence, sometimes with 
insertion of additional nucleotides. The duplicated region was variable in both 
size and location in different individuals but always fell within the JM domain 
encoded by exons  14 and  15.  The resulting transcripts  were  always  in-frame 
and  would  therefore  be  expected to  produce  functional  FLT3  chains.  These 
internal tandem duplications (ITDs) have also been detected in 3% of patients 
with myelodysplastic syndromes (Horiike et al, 1997; Yokota et al, 1997; Xu et 
al,  1999),  and  occasional  patients  with  ALL,  although  some  of the  latter 
patients had biphenotypic characteristics  (Xu et al,  1999; Nakao et al, 2000). 
They have not been found in patients with CML, chronic lymphoid leukaemia, 
non-Hodgkin's  lymphoma or multiple  myeloma  (Yokota  et al,  1997),  nor in 
normal individuals (Ishii et al,  1999). FLT3 mutations have also been found in 
exon 20 of the TKD. They include point mutations, deletions or insertions, and 
the most common nucleotide substitution changes an aspartic acid to tyrosine at 
amino  acid  835.  TKD  mutations  are  found  in  patients  with  AML 
(approximately 7%), MDS (2%-5%) (Horiike et al,  1997; Yokota et al,  1997; 
Xu et al, 1999), and ALL (1-3%) (Xu et al, 1999; Nakao et al, 2000).
Preliminary studies showed that FLT3/ITD mutations confer an adverse clinical 
outcome  in  patients  with  AML  (Kiyoi  et  al,  1999).  However,  this  was  a
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below the age of 60. Therefore, studies presented in this thesis aimed to assess 
the  clinical  significance  of FLT3/ITD  mutations  in  a  large  cohort  of adult 
patients below the age of 60, homogeneously treated according to MRC  10 and 
12 trial protocols (chapter 3). In the total group of 854 patients, 227 (27%) had 
a FLT3/ITD.  Mutations  were  found in all  FAB  subgroups  except MO  (0/14, 
p=0.02)  and  M7  (0/11,  p=0.04),  and  in  only  1   out  of  15  patients  with  M6 
(p=0.08). They were significantly more common in M3 (36%, p=0.004) and, in 
accord with this finding, the incidence of FLT3/ITD in patients with t(l5; 17) 
was  37%  (p=0.02).  A  high  frequency  of  mutations  was  also  observed  in 
patients  with  normal  cytogenetics  (34%,  p=0.0001).  Low  frequencies  were 
found in patients with t(8;21) and inv(16), (9%, p=0.0004 and 7% respectively, 
p=0.003).  FLT3/ITD+ patients had significantly  higher PB  white  cell  counts 
and  percentage  of BM  blast  cells  at  diagnosis  (p<0.0001).  Presence  of the 
mutation had a significant impact on clinical outcome, including OS, EFS, DFS 
and RR. The RR in patients with a FLT3/ITD at 5 years was 62% as opposed to 
44%  in those  without the mutation (p<0.001).  DFS, EFS  and  OS  were  32%, 
25%  and  35%  respectively in patients with a FLT3/ITD  as  opposed to 46%, 
39%  and  43%  in  those  without  the  mutation  (p<0.001  for  all  of them).  In 
multivariate  analysis,  the  presence  of a  FLT3/ITD  was  the  most  significant 
factor  adversely  affecting  RR  and  DFS  (p<  0.0001  for  both).  For  RR, 
cytogenetic  risk  (p<0.0001)  and  status  post  course  1   (p=0.001)  were  also 
relative risks, however less powerful.
Semi-quantitative radioactive PCR showed that a significant proportion of the 
FLT3/ITD+  patients  (51/224,  23%)  had  more  than  one  FLT3/ITD  mutation 
present. The majority of these patients (45/51, 88%) had two mutations but up 
to four were observed. In most patients, one mutation was predominant and the 
other(s) were minor components. There was a suggestion that patients with two 
or more mutations presented with a higher WBC count and a higher percentage 
of blasts in the BM at diagnosis. Patients with two or more mutations had the 
same RR as  those with a single mutation.  There  was,  however,  a suggestion 
that patients with two or more mutations had a worse OS, 36% at 5 years for 
one mutation, 21% for two or more (p=0.04). When the number of mutations (0
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the presence or absence of the mutation, then the number of mutations replaced 
the  latter  as  the  most  important  independent  variable  predicting  for  RR  and 
DFS.  This finding has not been investigated by other groups and will require 
further  clinical  and  biological  exploration  in  the  future  to  determine  its 
significance.
The  level  of mutant  detected  varied  between  0.5%  and  97%  of total  FLT3 
signal.  Most  patients  (201/224,  90%)  had  <60%  mutant.  In  a  significant 
proportion of patients (59, 26%), the level was consistent with a heterozygous 
mutation in all  or the majority of cells.  However,  in 23  patients  (10%) there 
was >60% mutant,  suggesting bi-allelic mutation or loss  of WT alleles.  This 
was associated with an older age at diagnosis, leucocytosis, poorer cytogenetic 
risk group and with FAB type M4. Survival analysis revealed that there was a 
suggestion of worse outcome in patients with >60% mutant, with a marginally 
increased  RR  in this  group  (85% versus  62%,  p  =0.06).  Since  these  studies 
were completed, several other groups have demonstrated the adverse outcome 
of FLT3/ITDs in adult, paediatric and elderly patients with AML, particularly 
where there is loss of the wild type allele (Whitman et al, 2001; Frohling et al, 
2002;  Stirewalt et al, 2001; Iwai et al,  1999; Meshinchi et al, 2001; Zwaan et 
al, 2002).As the presence of mutations in the FLT3  gene is a frequent finding 
in patients with AML, studies were then performed to explore their suitability 
as markers for MRD (chapter 4). Samples from 13 patients who presented with 
a FLT3  mutation were  studied at the time  of morphological  remission (<5% 
blasts  in  the  bone  marrow).  These  samples  revealed  that  in  remission  all 
patients lost their mutation(s), confirming that FLT3 mutations are leukaemia- 
specific.  Paired  PB  or  BM  samples  at  presentation  and  first  relapse  were 
available from 44 patients with de novo AML. Of the 24 patients studied who 
had only WT FLT3 alleles at presentation, 20 patients (83%) remained WT at 
first  relapse  and  4  patients  (17%)  acquired  a  FLT3  mutation.  Two  of these 
patients acquired a D835 mutation, and 2 patients gained a FLT3/ITD.
In 20 patients who had a FLT3 mutation at presentation,  18 were ITD+ and 2 
had D835Y mutations. Five patients (25%) lost their FLT3 mutation at relapse. 
Fifteen patients had a FLT3 mutation at both presentation and relapse. Two had
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relapsed  with  the  same  ITD  at  approximately  the  same  level.  Six  patients 
relapsed  with  the  same  ITD  but  at  an  increased  level,  where  the  median 
difference between presentation and relapse in the level of mutant was 29.5%. 
In  1   patient,  3  different ITDs were detected at diagnosis  (mutant levels 28%, 
3%,  1%  respectively),  but  only  the  predominant  mutation  was  present  at 
relapse.  Another patient had 2 different ITDs at diagnosis with mutant levels 
26% and 2%. Both were increased at relapse, 56% and  14% respectively. The 
remaining  patient  who  was  ITD+  at  presentation,  with  mutant  level  44%, 
relapsed  with  a  different  ITD,  mutant  level  60%.  This  study  of  paired 
diagnosis/relapse  samples  indicates  that  the  majority  of  patients  with 
FLT3/ITD  mutations  relapse  with  a  similar  or  higher  level  of  the  same 
mutation.  A  smaller  (25%)  but not  insignificant  number  of patients  lose  the 
mutation at relapse  or relapse with a new one  (5%).  For this  latter group of 
patients it seems that the FLT3/ITD is not present within the leukaemic stem 
cell that leads to disease relapse. It is also suggests that these mutations may be 
late hits during the process of leukaemogenesis, are unstable and thus should be 
used cautiously for the detection of minimal residual disease.
Given the high frequency of FLT3 mutations in patients with AML, FLT3 and 
its downstream signalling pathway are attractive targets for directed inhibition. 
Several promising tyrosine kinase inhibitors have recently been identified and 
studies were therefore performed to explore the cytotoxic effect of 4 different 
inhibitors on primary cells from patients with AML using a proliferation assay 
(chapter 5).  Initially,  12 fresh samples from patients with de novo AML were 
studied  using  the  tyrphostins  AG 1295  and  AG 1296.  Nine  patients  were 
FLT3/ITD  negative  and  3  FLT3/ITD  positive.  A  cytotoxic  effect  was  more 
apparent  in  cells  harbouring  a  mutant  receptor  compared  to  WT  FLT3, 
however,  the  difference  was  not  statistically  significant.  There  was  a  slight 
cytotoxic effect with AG 1296 in cells with FLT3/ITDs, but again this was not 
different from the control WT cells.
Subsequently, in order to determine whether the addition of standard cytotoxic 
agents  might  potentiate  the  effects  of tyrosine  kinase  inhibitors  on  primary
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AG 1295,  CEP-701  or PKC-412  incubated with  varying  doses  of cytarabine. 
Thawed  blast  cells  were  chosen  from  3  patients  with  FLT3  mutations  (2 
FLT3/ITD,  1  FLT3/TKD) and 3  patients with WT FLT3.  AG1295,  CEP-701 
and PKC-412, used as single agents, had a greater cytotoxic effect in blast cells 
harbouring a FLT3 mutation than in those with WT FLT3. This difference was 
statistically  significant  when  5pM  AG1295  and  20nM  CEP-701  were  used. 
Even  though  inhibitors  were  primarily  cytotoxic  to  cells  harbouring  FLT3 
mutations, CEP-701  and PKC-412 were also cytotoxic to blast cells with WT 
FLT3.  When  cytarabine  was  added,  different  patterns  of  cytotoxicity  were 
observed  for  each  patient  sample.  In  some  patients’  samples  inhibitor  or 
cytarabine  alone  produced  a  major  cytotoxic  effect,  whereas,  in  others  an 
additive effect was shown. Despite the wide variability in cell cytotoxicity from 
patient  to  patient,  the  in  vitro  data reported  in  chapter  5  suggest  that  FLT3 
inhibitors may have a role in the treatment of AML.
The studies presented in this thesis and results reported by other groups have 
shown that FLT3 ITDs play a major role in disease outcome, both in adult and 
paediatric  AML  (Kiyoi  et al,  1999;  Thiede  et  al,  2002;  Kondo  et al,  1999; 
Meshinchi et al, 2001). Nevertheless, many questions remain. For example, is 
the  size  of  the  ITD  predictive  of  worse  outcome  as  has  recently  been 
suggested? Stirewalt et al (2006) reported that with increasing size of ITD there 
is  a more  significant  loss of autoinhibitory function of FLT3,  translating  into 
inferior prognosis.  However,  large  studies  should address  this  observation as 
Kusec et al (2006) failed to confirm Stirewalt’s findings.
At the moment the molecular mechanism that generates a FLT3/ITD remains 
unclear.  Study of the accumulated sequences has revealed that ITD mutations 
essentially cluster in the tyrosine rich stretch from Y589 through Y599.  It has 
been suggested that if a lagging strand makes a hairpin at this position during 
DNA  replication  and  the  mismatch  repair  system  is  impaired,  a  FLT3/ITD 
would be generated by replication slippage (Kiyoi et al, 2006).
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mutation in at least a proportion of cells  in those  cases  with more than 50% 
mutant  is  due  to  hemizygosity  resulting  from  deletion  of the  wild  allele,  or 
homozygosity due to mitotic recombination. To date, strong evidence suggests 
that the latter is more likely to occur. FISH analysis in chromosome 13 failed to 
reveal  allelic  loss  at  13ql2  (Thiede  et  al,  2002),  while  recent  studies  have 
shown  that  the  high  degree  of association  between  uniparental  disomy  and 
homozygous  mutation  suggest  that  uniparental  disomy  might  account  for  a 
substantial  proportion  of  cases  exhibiting  a  lack  of  the  wild  type  allele 
(Fitzgibbon et al, 2005; Raghavan et al, 2005).
Although FLT3 is expressed on the surface of a high proportion of AML blast 
cells, little is known about the biologic and clinical significance of the level of 
FLT3  expressed  in  acute  leukaemia.  It  has  been  suggested  that  gene 
amplification might be a possible mechanism leading to overexpression of the 
transcript (Armstrong et al, 2003), however, this has only been demonstrated in 
an MLL-rearranged ALL cell line and not in primary AML cells.  Some studies 
have  evaluated  the  clinical  relevance  of  the  FLT3  transcript  level  and 
differences  in  FLT3  expression  in  specific  AML  subgroups,  and  have 
suggested  that  overexpression  of FLT3  is  an  unfavourable  prognostic  factor 
that might distinguish a novel disease entity in AML without FLT3 mutations 
(Ozeki et al, 2004; Kuchenbauer et al, 2005). However, as different techniques 
have been used (i.e. Northern blotting, RT-PCR), and the expression level has 
not been quantitatively determined, the clinical interpretation remains unclear. 
Moreover, the surface expression level of FLT3 protein has not been related to 
the  expression  level  of the  FLT3  transcript.  Nevertheless,  it  has  been  shown 
that the autophosphorylation of WT FLT3 induced by its overexpression can be 
inhibited  by  FLT3  kinase  inhibitors  (Armstrong  et  al,  2003),  and  therefore 
cases  with  overexpressed  FLT3  may  benefit  from  treatment  with  FLT3 
inhibitors.
The  data  on  paired  presentation-relapse  samples  in  this  thesis  suggests  that 
FLT3 mutations may be secondary events, as a small but consistent proportion 
of patients  with  AML  initially  harboring  FLT3/ITD  mutations  lacked  these
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mutations  occurred  at  a  later  stage  of  leukaemic  transformation,  and  that 
chemotherapy was  successful in eradicating the  clones  expressing the mutant 
FLT3.  Furthermore,  some  samples  were  found  to  contain  multiple  different 
FLT3/ITD  mutations, again suggesting that they were present in subclones of 
cells.  However, this will require further exploration as studies have suggested 
that in some patients FLT3/ITDs can be found in the leukaemic stem cell (Levis 
et  al,  2005).  They  sorted  primary  AML  samples  into  stem  cell-enriched 
CD34+/CD38‘ fractions and then analysed the sorted and unsorted cells for the 
FLT3  mutant:wild-type  ratio.  In  each  case,  the FLT3  mutant:wild-type  ratio 
was  not  changed  by  selection  of  CD34+/CD38"  cells,  implying  that  the 
mutations were present in the leukaemic stem cells.
The biology of FLT3  mutations and the role of these mutations  in promoting 
leukaemogenesis  remain  unclear.  The  constitutive  activation  of the  receptor 
induced by FLT3/ITDs promotes in vitro ligand independent proliferation and 
blocks myeloid differentiation of early haemopoietic cells (Kiyoi et al,  2002; 
Zheng et al, 2002). Wild type FLT3 appears to transduce its signalling cascade 
via  the  phosphatidylinositol-3  kinase  (PI3K)  and  Ras  pathways,  leading  to 
activation of AKT,  signal transducer and activator of transcription-5  (STAT), 
and  extracellular  signal regulated kinase-1   and 2  (ERK1/2)  (Hayakawa et al, 
2000; Mizuki et al, 2000;  Spiekermann et al, 2003). Presence of a FLT3/ITD 
confers  growth factor independent proliferation on haemopoietic  cells via the 
Ras and STAT5 pathways (Gilliland & Griffin, 2002). However, STAT5 might 
play a more critical role in FLT3/ITD signalling compared to the WT receptor 
(Mizuki  et al,  2000).  The  identification of proteins  that  co-operate  in FLT3- 
mediated  signalling  will  improve  the  understanding  of  how  constitutive 
activation  of  FLT3  induced  by  the  presence  of  an  ITD  participates  in 
leukaemogenesis. Microarray data might also help to bring further insight into 
the  role  of activated  FLT3  in leukaemogenesis  and  its  interaction with  other 
proteins.  Animal  data  suggest  that  transplantation  of FLT3/ITD  transduced 
bone  marrow  cells  into  irradiated  Balb/c  mice  rapidly  leads  to  a  fatal 
myeloproliferative  syndrome  characterised by marked neutrophil  leucocytosis 
and extramedullary haemopoiesis (Kelly et al, 2002a). FLT3 mutations appear
113to co-operate with the PML/RARA fusion gene, accelerating disease onset in a 
mouse  model  of  leukaemia  (Kelly  et  al,  2002b).  It  has  therefore  been 
hypothesised that the development of leukaemia requires the co-operation of at 
least  two  classes  of genetic  abnormalities,  one  which  impairs  differentiation 
and a second which promotes proliferation.  Thus, a FLT3/ITD may co-operate 
with for example, AML1/ETO, CBFb/MYHl 1, or PML/RARA to cause AML. 
However,  caution  must  be  exercised  in  extrapolating  results  of cell  lines  or 
murine models into human haemopoiesis. For example, enforced expression of 
a FLT3/ITD  in  human  CD34+ cells  conferred properties  of self-renewal  and 
enhanced erythropoiesis, but not a leukaemic phenotype  (Chung et al, 2005). 
Hence, it seems likely that in order for activated tyrosine kinases to contribute 
to the development of frank leukaemia, they must work in concert with other 
mutations that confer self-renewal to the blood cell.
Very recently, Falini  et al (2005) reported that in a high proportion of adults 
with AML the nucleophosmin (NPM1) gene is mutated resulting in an aberrant 
cytoplasmic  localisation  of the  product.  These  mutations  are  found  almost 
exclusively in patients with a normal karyotype and are highly associated with 
FLT3/ITDs,  suggesting  that  this  group  may  define  distinct  disease  entity. 
Several groups have tried to correlate the presence of the mutation with clinical 
outcome  and  it  has  become  apparent  that  presence  of NPM1  mutation  is 
associated  with  favourable  outcome,  except  in  the  presence  of a  FLT3/ITD 
(Suzuki et al, 2005; Dohner et al, 2005; Schnittger et al, 2005). Taken together, 
these data indicate that further work will be needed to unfold the mechanisms 
by which such mutations co-operate and contribute to leukaemogenesis.
In  relation  to  treatment,  large  prospective  trials  will  be  required  in  order to 
determine  therapeutic  strategies  which  potentially  can  negate  the  adverse 
clinical outcome associated with FLT3/ITDs. Published data has suggested that 
protocols incorporating a high dose of cytarabine might improve outcome. For 
example, in the studies presented in this thesis on patients treated in the MRC 
AML 10 and 12 trials, the dose of cytarabine in the protocols ranged from 5.6 to 
11.6  g/m2, whilst  in the  German trials which did not observe  an  impact of a 
FLT3/ITD on OS  (AML-96, AMLCG92 and AMLCG99), the cytarabine dose
114was up to 8  fold higher, with the lowest dose at 22.4 g/m2 and the highest at 
92.8  g/m2  (Schnittger et al,  2002).  Another study has  supported the  idea that 
intensive chemotherapy  during  induction and consolidation may abrogate the 
adverse  outcome  in FLT3/ITD  patients  (Boissel  et al,  2002).  They evaluated 
outcome  in patients  randomised to receive  higher than conventional doses  of 
classical  3+7  induction  regimes,  with  protocol  arms  containing  double 
induction  and  timed  sequential  chemotherapy.  They  found  no  difference  in 
relapse-free  survival  between  FLT3/ITD  positive  and  negative  patients, 
although there was a trend for worse OS in the FLT3/ITD patients (p = 0.09). 
Although the  cumulative  doses of cytarabine and anthracycline  did not differ 
from those used in the MRC protocol, this potential drug intensification may 
have produced profound cell toxicity able to overcome any chemoresistance of 
remaining leukaemic cells.
However,  these  suggestions  rely on retrospective  data  and  small  numbers  of 
patients  with heterogeneous  characteristics  in relation to  age  and cytogenetic 
risk  group.  Therefore,  it  will  be  important  for  clinicians  to  design  well 
controlled randomised studies incorporating FLT3/ITDs in risk assessment and 
stratification.  For  example,  the  BFM  study  group  has  decided  to  stratify 
patients  with  FLT3/ITDs  to  the  high  risk  arm  in  their  AML-2004  trial  in 
paediatric  patients  (Zwaan  et  al,  2004).  This  study  involves  a  first 
randomisation  between  cytarabine,  daunorubicin,  etoposide  (ADE)  and 
cytarabine,  idarubicin,  etoposide  (AIE),  with  subsequent  risk  assignment 
between high and standard risk disease. Patients with FLT3/ITDs are assigned 
to the high risk arm and receive high dose cytarabine with mitoxantrone, with a 
second randomisation between cytarabine/idarubicin or cytarabine/idarubicin in 
combination with 2-chloro-2-deoxyadenosine (2-CDA).  Another possibility is 
that strategies incorporating high dose procedures might have to play a role in 
patients with FLT3 ITDs. This has been evaluated in 1135 adult patients treated 
according to UK MRC AML 10 and 12 protocols. In 141 patients who received 
an autograft in CR1, FLT3/ITDs remained a poor prognostic factor for relapse. 
In the allograft setting, the impact of a FLT3/ITD on the relapse rate was less 
marked,  but  in  a  donor-versus-no  donor  analysis,  there  was  no  significant 
difference  in the benefit of a donor with regard to relapse in FLT3/ITD+ and
115FLT3/ITD-  patients  (Gale  et al,  2005).  Currently,  a  Spanish trial  is  awaiting 
ethical approval in order to randomise patients with standard risk disease and 
FLT3 mutations either to receive or not a stem cell transplant in CR1  (personal 
communication, Dr R Martino).
The role of FLT3 inhibitors in AML needs to be explored in future studies. In 
vitro  studies  have  shown that FLT3  inhibitors  can induce  cytotoxicity in cell 
lines and primary AML cells.  Several Phase I and II trials have been published, 
however, the efficacy of these agents in disease outcome remains unimpressive 
(Smith et al, 2004; Stone et al, 2004). Even though FLT3 inhibitors can reduce 
the number of blast cells in the peripheral blood/marrow, complete remissions 
rarely occur and are not durable. As studies have suggested that FLT mutations 
in some patients might represent secondary events, the use of FLT3  inhibitors 
as  monotherapy  is  unlikely  to  be  effective.  However,  presuming  that  FLT3 
inhibition  can  be  incorporated  into  standard  chemotherapy  protocols,  large 
clinical studies will be required to explore potential efficacy. It should be noted 
that  the  development  of  resistance  to  tyrosine  kinase  inhibitors  can  be 
anticipated, however, it might be possible to overcome such resistance by using 
alternative inhibitors with different chemical structures. The structure of FLT3 
has  been  described  by  Griffith  et  al  and  may  provide  insight  into  the 
mechanism  by  which  the  JM  domain  in  the  wild  type  receptor  inhibits  the 
catalytic  activity  of the  kinase  domain  Since  this  interaction  is  disrupted  in 
FLT3/ITDs, this may open a window of opportunity for the design of specific 
FLT3  inhibitors.  Finally, AML patients whose  leukaemic blasts are  shown to 
over-express  WT  FLT3  that  is  constitutively  activated  by  FL  comprise  an 
additional population that should be considered for future trials.
In conclusion, despite some insight into the biology of FLT3, its leukaemogenic 
properties  remain  largely  unknown  and  will  require  further  exploration. 
Ultimately  these  studies  should  reveal  novel  therapeutic  targets  for  the 
treatment of AML.
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147Appendix
Treatment protocols 
AML 10 trial
In AML  10  trial  patients  were randomised to  receive  2  courses  of induction 
therapy  of  either  DAT  (daunorubicin,  cytarabine,  6-thioguanine):  3+10  for 
course  1   and 3+8  for course 2, or ADE (cytarabine, daunorubicin, etoposide): 
10+3+5 for course 1  and 8+3+5 for course 2. Both arms then received 2 courses 
of  consolidation  therapy  of  MACE  (amsacrine,  cytarabine,  etoposide)  and 
MID  AC  (mitozantrone,  cytarabine).  Patients  achieving  CR  were  allowed  to 
proceed  to  an  allogeneic  transplant  if  a  suitable  HLA-matched  donor  was 
available  or  were  eligible  to  be  randomized  to  receive  either  an  autologous 
transplant or no further treatment.
AML 12 trial
Patients entered into the AML 12 trial were randomized to receive one course 
of  induction  therapy  of  either  ADE  (10+3+5)  or  MAE  (mitozantrone, 
cytarabine,  etoposide:  3+10+5).  BM  remission  status  was  then  assessed  and 
patients were assigned to one of three risk groups, good, standard or poor based 
on the  cytogenetics and response to the first cycle  of therapy.  Patients  in the 
good  and  standard  risk  categories  received  a  second  course  of  induction 
chemotherapy  as  before,  either ADE  (8+3+5)  or  MAE  (3+8+5),  then a third 
course  of  MACE  consolidation  therapy.  Good  risk  patients  were  then 
randomized to receive either just one further course of chemotherapy (MID AC) 
or a fourth course of ICE (idarubicin, cytarabine, etoposide) plus a fifth course 
of MID  AC.  Standard risk patients were randomized to receive either MID  AC, 
or ICE then MID AC, or ICE followed by a transplant, or a transplant only, in a 
4 versus 5 courses and transplant versus chemotherapy 2 x 2  design. Patients in 
the  transplant  groups  received  an  allogeneic  transplant  if a  suitable  matched 
sibling  donor  was  available  or,  if  not,  an  autologous  transplant.  Patients
148assigned  to  the  poor  risk  group  were  entered  into  the  MRC  trial  for 
refractory/relapsed  AML  and  were  randomized  to  receive  re-induction 
chemotherapy with either standard (10+3+5 then 8+3+5) or continuous ADE, 
and then further randomized to receive either cyclosporin A or not.
For those patients with a clinical  diagnosis  of acute promyelocytic leukemia, 
all-trans  retinoic  acid,  either  as  a  short  or  extended  course,  was  given  in 
addition to the chemotherapy described above.
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